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CHAPTER 1
GENERAL INTRODUCTION AND AIMS AND OUTLINE
OF THE THESIS
Based on the article:
Studying the genetics of Hirschsprung’s disease: unraveling an oligogenic disorder. 
A.S. Brooks, B.A. Oostra, R.M.W. Hofstra.
Clin Genet 2005;67:6-14 
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INTRODUCTION 
1. General introduction 
1.1 History, definition and frequency of Hirschsprung disease
Harald Hirschsprung (1830-1916) was the senior physician at Denmark’s oldest children’s hospital, 
Queen Louise Children’s Hospital, Copenhagen. He was appointed as a professor in Pediatrics in 
1877 1. He described 2 boys who died at 8 and 11 months of age respectively, having presented 
with a typical clinical history of severe constipation 2. By 1904 Hirschsprung had seen 10 cases; 9 
were boys. He focused on the dilated colon as the source of the patients’ problems. However, the 
earliest observation of this clinical entity is probably attributed to the famous Frederik Ruysch (1638-
1731). The city council of Amsterdam not only appointed him as praelector but also as professor of 
anatomy, surgery and botany and overseer of midwifery in Amsterdam 3. He reported a girl with 
“enormis intestini colo dilatatio” 4. 
What Hirschsprung was describing and what we now call Hirschsprung disease (HSCR) or 
congenital megacolon, is clinically characterized by failure to pass meconium (the first stool) within 
48 hours after birth, a distended abdomen, vomiting or neonatal enterocolitis 5. HSCR is the most 
common cause of bowel obstruction in childhood and occurs worldwide. Chronic constipation is 
the major presentation in childhood. The estimated prevalence in the population is 1:5000 live born 
children 6-11, which means approximately 40 children are born each year in the Netherlands with 
this congenital malformation (2003: 200.297 live born children, 2004: 194.007 live born children, 
CBS http://statline.cbs.nl).
1.2 Diagnosis and treatment of HSCR
Although the clinical condition became well recognized, the histopathological features of HSCR 
were not understood until 1948. Histopathology of the bowel wall in a full-thickness rectal biopsy 
is the golden standard in reaching the diagnosis 12. It characterizes this congenital abnormality by 
the absence of  ganglia (groups of neurons) in the myenteric (or Auerbach) plexus, between the 
circular and longitudinal muscle layers of the gut, and in the submucosal (or Meissner) plexus, 
internal to the circular muscle layer 13, 14. More frequently, because it is less invasive and is 
associated with less complications, a suction rectal biopsy is performed, demonstrating an increase 
in acetyl cholinesterase (AChE) activity in the lamina propria and muscularis mucosae; which is 
pathognomonic for HSCR 15. Usually two pieces are taken: one is frozen and processed for AChE 
histochemistry and counterstained with hematoxylin (fig 1), and the other is embedded in paraffin 
and the sections are stained with hematoxylin and eosin to examine for the presence of ganglion 
cells. It is important to note that on a water-soluble contrast or barium enema radiograph the 
grossly abnormal-looking, distended colon (“megacolon”) contains the normal enteric nervous 
system (ENS). Often a transition zone between the normal and agaglionic bowel is seen (fig 2). 
Anorectal manometry can also aid in the diagnosis of HSCR through the absence of the rectoanal 
inhibitory reflex after a distention bolus 16. The department of Pediatric Surgery of the Erasmus 
MC/Sophia Children’s Hospital advocates the diagnostic approach of a child clinically suspected of 
HSCR consisting of radiographic studies (in neonates a water-soluble contrast enema is preferred), 
histopathological studies (suction biopsy and/or a full thickness biopsy), and anorectal manometry 
according to the diagnostic guidelines of the Dutch Pediatric Surgery Association. 
The treatment of HSCR is surgical and is based on the resection of the aganglionic 
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segment of intestine; the chief difficulty encountered by pediatric surgeons is precisely establishing 
the proximal extent of the functional abnormality. Swenson and Bill performed the first corrective 
procedure for HSCR-rectosigmoidectomy and primary colo-anal anastomosis 17. 
Figure 1 
Histopathological findings in a patient 
with HSCR. Acetylcholinesterase 
histochemical staining in HSCR. 
Increased acetylcholinesterase stain-
ing with coarse, thick nerve twigs 
surrounding muscularis mucosa and 
extending into the lamina propria. 
Courtesy Dr. J. den Hollander.
Figure 2 
Water-soluble contrast enema of a 
patient showing the typical transition 
zone in the rectosigmoid region, 
which is the most common location.
Courtesy Dr. M. Lequin.
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Throughout the years, all kinds of variants to remove the aganglionic bowel and to reconstruct the 
intestinal tract by bringing the normally innervated bowel down to the anus while preserving normal 
sphincter function have been described. Many operations have been devised to accomplish these 
goals, but the most commonly performed at the present time are the Swenson, Duhamel, Soave 
and Rehbein procedures 1. Current trends include primary neonatal and laparoscopic assisted pull-
through, and transanal approaches 18-22. 
When not treated correctly, HSCR may lead to death. However, the mortality rate has dropped 
from >75% in the 1940’s to <2% in the 21st century, a trend which is associated with advancements 
in peri-operative treatment of children over the years  1, 23. The most serious complication of HSCR 
is enterocolitis, in which necrosis and ulcerations affect the dilated proximal segment of the colon 
and may extend into the small bowel 23, 24. It is characterized by fever, abdominal distention, and 
diarrhea, which may be severe and lead to life-threatening dehydration or sepsis.  
1.3 Pathogenesis; normal and abnormal embryology of the enteric nervous 
system
HSCR results from a failure of neural crest cells to migrate, proliferate, differentiate or survive 
in the bowel wall to form both plexuses of the ENS 25, 26. The ENS is a division of the autonomic 
nervous system and is defined as the system of neurons and their supporting cells (i.e. glial cells) 
that is present within the enteric wall. The ENS mediates motility reflexes and plays a major role 
in controlling water and electrolyte transport by the mucosal epithelium; it also regulates intestinal 
blood supply. 
The development of the ENS is the focus of many different types of studies including e.g. 
studies of human congenital malformations of the ENS (i.e. the study of familial cases of HSCR, as 
discussed in paragraph 2.1), classic embryological ablation studies in chick embryo 27 and, transgenic 
experiments in rodents 28-30. In addition, data from developmental studies of the ENS in fish and 
amphibians are accumulating 31-34, supporting the notion that the network of molecules and receptors 
that determine the development of the ENS is ancient since it is conserved in detail among many 
species (fish, amphibians, birds, and mammals).
Defects that interfere with cell migration could arise in the neural crest cells themselves, 
or in their local environment, either at the site of their origin, in their migration pathways towards 
the gut, in the gut in general, or in the normal ganglionic zone of the gut. Neural crest cells are 
produced from the entire length of the neural axis but only certain tightly defined regions of the 
neural crest give rise to the ENS, predominantly the vagal neural crest adjacent to the first seven 
somites-the primitive segments of the body- 26, 35.These precursor cells first migrate from the vagal 
neural crest into the rostral end of the intestinal tract early in embryonic life, and then migrate along 
the gut in a rostrocaudal manner to colonize the entire intestine. In the human fetus, neural crest 
cells migrate from the 5th to 12th week of gestation 25, in mice this process is completed by E13,5 36-38. 
The role of the sacral neural crest in the development of the distal part of the ENS is still disputed 
(for review see Burns) 39. 
The neural crest cells also produce the cells of the sympathic and parasympathic nervous 
systems, dorsal root ganglia, and of several other cell types in specific locations (such as neuronal, 
endocrine and paraendocrine, craniofacial, conotruncal heart, and pigmentary tissues) 40, 41 . 
HSCR is therefore classified as a “neurocristopathy” 42 . Neurocristopathies encompass tumors, 
malformations, and single or multiple abnormalities of tissues mentioned above. 
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1.4 Classification of HSCR
In the majority of cases the lack of ganglion cells is restricted to the sigmoid and the rectum (fig 3). 
This form is called short-segment HSCR (S-HSCR). However, in 20% of cases the aganglionosis 
extends proximally 6, 9 which could be involving the complete colon and the terminal portion of 
the ileum (total colonic aganglionosis or TCA). In a small proportion of cases the aganglionosis 
extends to the whole bowel 43 .This is a lethal condition. These two latter forms are classified 
as long-segment or L-HSCR. However, not everybody is using the same classification; sometimes 
aganglionosis extending to the splenic flexure is called S-HSCR. 
2. Studying the genetics of HSCR
What was the rationale for investigating a genetic basis for HSCR? Several lines of evidence 
suggested the involvement of genetic factors in the etiology of HSCR. First, familial occurrence 
ranges from approximately 5 -15% 6, 9, 44. Badner and others performed complex segregation 
analysis of data on 487 probands and their families. They could show a male predominance of HSCR 
(3.9 males:1 female), consistent with other observations that HSCR is more common in boys  6-10, 
44. This unbalanced sex ratio suggests a genetic component 45. Furthermore they demonstrated 
an elevated risk to sibs (4% or 0.04), as compared with the population frequency of 1 in 5000 
(0.0002) (risk ratio λ=200) 45. It was observed that the sex ratio decreased and the recurrence 
risk to sibs increased as the aganglionosis became more extensive. For the cases with aganglionosis 
beyond the sigmoid colon, the mode of inheritance was compatible with a dominant gene with 
incomplete penetrance, whereas for cases with S-HSCR, the inheritance pattern was equally likely 
to be multifactorial or recessive with very low penetrance. Another indication for involvement of 
genetic factors in HSCR comes from the association of HSCR with chromosomal aberrations such 
as trisomy 21 6-11, 46 (it is estimated that 2-10% of HSCR cases have Down syndrome, whereas 
5‰-1.4% of Down syndrome cases have HSCR 47, 48) and structural anomalies of chromosome 
2,7,10,13 and 20 49-53. The association of HSCR with a myriad of Mendelian inherited syndromes 
also indicated a possible genetic basis. Finally, the existence of several animal models of colonic 
aganglionosis showing specific Mendelian modes of inheritance was compatible with the notion that 
genetic factors were involved in HSCR as already mentioned in paragraph 1.3 54, 55. 
Figure 3 
Classification of HSCR on the 
basis of the length of intestine 
with aganglionosis.
A=S-HSCR
B=L-HSCR
C=TCA
A
B
C
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The search for genes involved in HSCR is a striking example of combining several strategies for the 
genetic dissection of a disorder with a complex etiology 56-58. Furthermore this search illustrates 
the deeply interdependent relationship between clinically driven research and basic developmental 
studies. HSCR is mainly seen as a sporadic disorder and in most cases this is S-HSCR. In a minority 
of cases (5-15%) 6, the disease shows a clear familial occurrence mostly with a Mendelian autosomal 
dominant pattern with incomplete penetrance and variable expression 45. One in three children 
has additional congenital anomalies. However, in only a minority of these children is a syndrome 
diagnosed 10, 11, 44, 59, 60. The syndromes include chromosomal abnormalities (like trisomy 21) and 
Mendelian inherited syndromes, as extensively reviewed by Amiel and Lyonnet 61 (see fig 4 for 
examples of Mendelian syndromes associated with HSCR). 
Figure 4  
Examples of syndromic forms of HSCR.
1. Mowat-Wilson syndrome. Same patient at different ages.
Note the pointed chin, horizontal eyebrows and the uplifted earlobes.
Courtesy Dr. M. Wilson
2. Goldberg-Shprintzen syndrome. Same patient at the age of 8 months, 4 years and 6 years.
Note hypertelorism, synophrys and arched eyebrows. 
Clouding of the cornea is present at the age of 6 years.
3. Shah-Waardenburg syndrome. Note the white forelock in a neonate.
1
2
3
20 1
For some of these Mendelian syndromes the genes have been identified. In the next paragraphs 
the genes and loci identified for non-syndromic (isolated) and syndromic forms of HSCR (table 1, 2 
and 3) are reviewed. We will illustrate the overlap between syndromic and non-syndromic forms 
of HSCR, highlighting the fact that variable expression and reduced penetrance in those syndromes 
can be due to abnormalities in other non-syndromic HSCR susceptibility genes that act on the same 
or on interdependent developmental pathways. In contrast, we speculate that variants in new genes 
associated with rare syndromic forms might be discovered that may also confer a low risk in non-
syndromic HSCR.
2.1 Non-syndromic HSCR: genes and loci involved 
Multigenerational families with HSCR
Classical linkage mapping in large multigenerational families enriched for L-HSCR resulted 
in the mapping of a HSCR gene on 10q11.2 62, 63. Linkage was directed by information based on 
chromosomal aberrations in 2 HSCR patients  51, 64. Both patients with total colonic aganglionosis 
showed an interstitial deletion of 10q11.2. RET (REarranged during Transfection), which encodes a 
receptor tyrosine kinase, and which was considered to be a good positional and functional candidate 
gene mainly based on expression studies. RET is predominantly expressed in neural crest derived 
tissues and tumors 65, 66. The hypothesis of RET being a perfect candidate gene was strengthened 
by the finding of mutations in RET in a cancer syndrome, namely multiple endocrine neoplasia type 
2A (MEN2A) 67, 68. MEN2A is a cancer syndrome characterized by medullary thyroid carcinoma 
(MTC), phaechromacytoma, and hyperplasia of the parathyroid glands. The observation of the co-
occurrence of MEN2A and HSCR in some families made a shared pathogenesis likely 63. Shortly 
after the first RET mutations in HSCR patients were reported 69, 70. 
All published families with HSCR, except one, are linked to RET  71. In 50% of the 
multigenerational families a mutation in the coding sequence of RET was identified 72, 73. The 
mutation yield of only 50% in HSCR families might be explained by the presence of mutations 
located outside the coding region of the RET gene in elements that control timing, location and /or 
level of gene expression. On the other hand the linkage to 10q in families without a RET coding 
sequence mutation, might also be explained by a susceptibility gene at a locus near RET and which is 
in linkage disequilibrium with RET, although so far no direct evidence points in that direction.
Failure to detect the biologically relevant RET mutations in half the reported HSCR families 
resulted in additional linkage studies using classical and non-parametric linkage methods. Linkage 
to RET was found in 11 out of 12 multigenerational families. In 6 of these families a pathogenic RET 
mutation was found. More interestingly a locus at 9q31 was found to segregate with the disease 
phenotype. This 9q31 locus was found in those families that did not have a mutation in the coding 
sequence of RET. It was suggested that the combination of these specific loci most likely explains the 
disease phenotype in these families 71.
Siblings with HSCR
As mentioned above, classical linkage mapping led to the identification of the RET gene as the major 
locus in families in which both S-HSCR and L-HSCR was segregating. However, these studies failed 
to explain the much more frequent occurrence of S-HSCR. Therefore series of siblings with S-
HSCR were studied in a genomic wide screen for susceptibility factors other than RET. All 67 sib-
pairs, excluding 2, showed haplotype sharing of 10q11.2. In 40% of these sib pairs a mutation in 
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the coding sequence of RET was reported, again underlining the central role of RET in HSCR. Two 
additional susceptibility loci, one at 3p21 and one at 19q12, were identified, and conferred a lower 
risk than RET 74. This study showed that what seemed to be “simple” dominant inheritance proved 
not to be in the small HSCR families studied: heterozygous mutations at 3 different loci worked in 
concert and explained in a multiplicative model the genetics of S-HSCR. Moreover, multiplication of 
the estimated frequencies of these 3 susceptibility alleles is consistent with the frequency of HSCR 
in the population 6. Furthermore, when only the RET negative siblings and the siblings with “mild” 
RET changes were analyzed, non-random allele sharing at 9q31 was confirmed. This again suggests 
a modifier locus at 9q31, as was already proven to exist in multigenerational families enriched for 
L-HSCR 71. 
The sporadic HSCR patient
Direct mutation analysis revealed that mutations of the RET gene are also the most common 
genetic cause of HSCR in sporadic patients identified today although they are only found in 15-
35% of the cases 72, 73. For the genetic dissection of the sporadic form of HSCR a candidate-gene/
association-analysis approach was chosen. As only 50% of the RET linked families had mutations, 
RET involvement without an obvious mutation was also considered in sporadic HSCR. Therefore 
case-control or trio-design studies evaluated haplotypes encompassing the RET locus. All studies 
(all performed on European HSCR patients originating from Spain, Italy, Germany, France and the 
Netherlands) showed the same alleles/haplotypes to be over represented in sporadic HSCR 75-
80. Up to 55% of the patients were carrier of the same haplotype and consequently the same 
unidentified variant whereas this variant was only present in 16% of the controls 79. This same 
haplotype has a 66% frequency in Chinese sporadic HSCR patients 81. In Asian American and 
European American control patients, the common non-coding RET variant (named RET+3) was 
identified in 45% and 25% of cases respectively; however, it is virtually absent in African Americans 
where it has a frequency of less than 1% 82. The high frequency of this common non-coding RET 
variant in Asians probably correlates with an increased frequency of S-HSCR among Asian American 
newborns 83. The data clearly show that the RET gene is also the major gene in sporadic HSCR cases, 
even when no clear mutation can be identified. Only one variant or one combination of ancestral 
variants in RET, specifically in the 5’ end region (upstream the gene and in intron 1), contribute 
to the development of the majority of HSCR worldwide. Remarkably, a dose dependent effect 
seems present; homozygosity for certain RET haplotypes is associated with a higher odds ratio 79, 80. 
The question remains: which of the identified variants is contributing to the disease development? 
Several candidates have already been put forward 78, 84, 85. Both Fitze et al.78 and Garcia Barcelo et 
al. 84 showed reduced expression associated with two risk-associated SNPs in the basal promoter. 
However, Griseri et al. could not confirm these findings 85. Furthermore, Garcia-Barcelo and co-
workers showed that these two basal promoter SNPs overlap a TTF-1 binding site and that TTF-1 
activated RET transcription is also decreased by the HSCR-associated SNPs. In addition to these 
possible disease associated SNPs, two SNPs (RET3+, rs2435357 and IVS+9494, rs2506004) in this 
common risk haplotype are particular interesting as disease-associated RET variants, because of the 
homology and evolutionary conservation between rodents and primates, the differences in allele 
frequencies among patients and controls, and the fact that these SNPs show the highest association 
with the disease 82, 86. Recent data show that RET3+ might lie within, and might compromise 
the activity of an enhancer-like sequence in RET intron 1 82.  IVS+9494 is located in a region also 
conserved in nonmammalian species, and was therefore considered to be the most likely HSCR-
associated variant 86. 
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Direct mutation analysis in GDNF (glial cell line derived neurotrophic factor) and Neurturin, both 
encoding ligands of the RET protein and therefore considered as plausible functional candidate 
genes, has rarely revealed mutations in sporadic HSCR patients. Single mutations in these genes are 
thought to contribute to the phenotype but are insufficient to cause HSCR 87 88.
2.2 Syndromic HSCR: autosomal recessive forms
Waardenburg syndrome type 4 or Shah-Waardenburg syndrome (OMIM 277580) is characterized 
by sensorineural deafness, pigmentary abnormalities of the skin, eyes (heterochromia of the irises) 
and hair (poliosis or white forelock) and HSCR 89 90. Shah-Waardenburg syndrome is traditionally 
classified as a “neurocristopathy”; both melanocytes and ganglion cells that migrate into the gut are 
neural-crest-derived 42. The first locus for this syndromic form of HSCR was mapped to 13q22 by 
an identity by descent approach in an inbred Mennonite population with considerable degrees of 
consanguinity and a ten-fold increased prevalence of HSCR indicating a high carrier frequency for a 
HSCR related mutation 91. The affected cases shared a common ancestor 12 generations ago, and 
thus should be classified as a very young genetic isolate (<20 generations). The advantage of a young 
isolate is the fact that the genetic make-up of this isolated population more closely resembles that of 
the general population 92. However in the case of the Mennonites it is important to realize that the 
founders were Swiss immigrants and therefore the resemblance to the general Caucasian population 
in the US might probably be limited 93. Again as was the case with the identification of a HSCR locus 
on chromosome 10 (RET), the finding of aberrations (interstitial deletions) of chromosome 13 in 
HSCR cases helped to pinpoint this region as a HSCR related locus 52, 94. The identification of the 
EDNRB (endothelin receptor-B) gene at 13q22 as the disease gene in this inbred population was 
further facilitated by knowledge based on phenotypic similarity to a mouse mutant 29, 95. 
Because only 87% of the affected individuals in the inbred Mennonite population carried a 
missense mutation in the EDNRB gene a genome-wide association study in 43 Mennonite family 
trios was performed leading to the identification of a susceptibility locus on 16q23 in this kindred 
96. Furthermore, a clear association with certain RET alleles was demonstrated in the Mennonite 
population. However, after extensive mutation analysis, no mutation was identified of the RET 
gene in a selected panel of Mennonite HSCR patients. Apart from RET and EDNRB, none of the 
other HSCR genes or loci (on 9q31, 3p21, 19q31) showed an association. So even in this inbred 
population, mutations and/or variants in multiple genes at 3 loci cause HSCR with, again, a role 
for the RET gene or for one or more HSCR-susceptibility variants in linkage disequilibrium with 
RET. These data showed that variable expression and incomplete penetrance in syndromic HSCR 
(i.e. WS) is not only associated with variants in a syndromic HSCR gene (i.e. EDNRB) but is most 
probably also due to an abnormality in a gene involved in non-syndromic HSCR disease (RET) that 
acts in another neural crest development-related pathway. Association with 16q23 has not been 
confirmed in a non-Mennonite dataset, so it is unclear whether this susceptibility locus is unique 
for this inbred population or may also confer a low risk in the general population. No evidence was 
found for haplotype sharing with 16q23 in the 67 siblings with non-syndromic S-HSCR 74. However, 
the elucidation of the gene located at 16q23 may yield clues toward other key proteins involved in 
HSCR genesis that may play a role in the general HSCR population.     
The finding of mutations in the gene encoding the ligand of EDNRB, that is EDN3 (endothelin-
3) in Shah-Waardenburg patients was not surprising. A well-informed functional candidate gene 
approach and knowledge based on a mouse model helped in its identification 28, 97, 98. It shows that two 
different genes in the same developmental pathway can cause the same phenotype. Heterozygous 
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mutations in these two genes were found in less than 5% of the non-syndromic HSCR population. 
Illustrating again the fact that although rare, mutations in these genes indeed confer a risk in non-
syndromic forms of HSCR 99-103.      
2.3 Syndromic HSCR: autosomal dominant forms 
To date four autosomal dominant forms with predominantly de novo mutations are known in 
syndromic HSCR patients. To decipher the molecular basis of three syndromes, knowledge derived 
from animal models was crucial. 
In one patient with HSCR, a complex heart defect and autonomic dysfunction, a mutation 
in ECE1 (endothelin converting enzyme) was reported 104. ECE1 was considered as a candidate gene 
because it was known that Ece1+/- mice are normal, whereas Ece1-/- mice exhibit neonatal lethality 
because of craniofacial and cardiac defects. In addition, Ece1-/- newborns lack enteric ganglia in the 
terminal colon 30. 
A dominant form of Shah-Waardenburg syndrome, sometimes with additional neurological 
features such as ataxia, leukodystrophy, polyneuropathy, is caused by mutations in SOX10 (sex-
determining region Y-related HMG-box gene 10) 105, a gene that was suspected to be a candidate 
for HSCR because of the Dominant megacolon or Dom mouse, a spontaneous mouse mutant with 
aganglionosis 106. These mice have aganglionosis of the colon, pigmentation defects, and a loss of 
neurons and glia in the peripheral nervous system, consistent with the human phenotype.  
SOX10 mutations are associated with 3 phenotypes: classical Shah-Waardenburg syndrome, 
a complex neurocristopathy also named PCWH (OMIM 609136); peripheral demyelinating 
neuropathy, central dysmyelinating leukodystrophy, Waardenburg syndrome, HSCR 107, 108 and 
Yemenite deaf-blind-hypopigmentation syndrome 109.
In 75% the classical Shah-Waardenburg cases the mutations are de novo dominant, as 
reviewed by Verheij and Hofstra 103. However, in the 25% of cases with an inherited mutation, 
the parent has no clinical features of Shah-Waardenburg syndrome. The reason for existence of so 
many de novo SOX10 mutations may be that the severity of most associated phenotypes precludes 
reproduction. To explain the inheritance of several SOX10 mutations one must assume that these 
mutations have incomplete penetrance or variable expression with only mild features in the parent. 
This suggests the existence of modifying factors in the parent and/or the patient. 
Congenital Central Hypoventilation syndrome (CCHS) or Ondine’s curse (OMIM 209880) 
is a life-threatening disorder characterized by failure of the autonomic control of breathing, especially 
during sleep 110. The observation of HSCR in an estimated 15-20% of CCHS cases suggests a 
developmental link and common disease pathogenesis. Also, approximately 1.5% of HSCR cases 
have CCHS 111. This specific combination is named Haddad syndrome 112, 113. Therefore several 
known HSCR genes (RET, GDNF, EDN3) were considered as candidate genes for CCHS 114 115, 116. 
Recently the major CCHS gene, PHOX2B (the paired-like homeobox) gene or PMX2b on 4p12, has 
been identified 117. PHOX2B was considered to be a candidate gene in CCHS because in mice, the 
development of the reflex circuits of the autonomic nervous system is dependent on Phox2b 118.  At 
present PHOX2B mutations have been reported in over 300 CCHS patients, a minority of whom 
also had histologically proven HSCR 116, 117, 119-123. Among 66 CCHS cases with PHOX2B mutations, 
4 parents of the 43 pairs of parents available for DNA analysis, were mosaic for the mutation. This 
suggests that not all mutations in CCHS probands with healthy parents are de novo mutations 119.  
The accurate syndrome delineation of HSCR with microcephaly and mental retardation in 
24 1
cases with deletions of chromosome 2q22, led Mowat et al, to the conclusion that this entity should 
be separated from the clinical entity originally described by Goldberg and Shprintzen as an autosomal 
recessive syndrome 124, 125. De novo mutations in ZFHX1B (zinc finger homeo box 1B, also known as 
Smad interacting protein or Sip1) were described in HSCR patients with microcephaly. This gene 
was located in the deleted segment at 2q22 from HSCR patients with a de novo t (2;13)(q22;q22) 
and t (2;11)(q22.2;q21). Again, a chromosomal abnormality helped to identify the culprit gene by 
using a positional cloning approach 126 127. At present reports of over 100 cases with a  ZFHX1B 
mutation and variable clinical features-now named Mowat-Wilson syndrome- have been published 
127-141. HSCR was a variable feature in 40-70% of cases 133. 
Goldberg-Shprintzen syndrome is another clinical entity that is unlinked to 2q22 (chapter 
3). Specifically, the facial features in Goldberg-Shprintzen syndrome appear to be different from 
those in Mowat-Wilson syndrome. Most striking is the difference in configuration of the eyebrows. 
In Goldberg-Shprintzen syndrome the eyebrows are arched, and may cross the midline (synophrys), 
while in Mowat -Wilson syndrome the eyebrows are horizontal (see fig 4). Furthermore a substantial 
part of patients with Mowat-Wilson syndrome have epilepsy and agenesis of the corpus callosum, 
while these features are rarely reported in Goldberg-Shprintzen syndrome 124, 125, 127-130, 133.
2.4. Relationship between gene mutations and aganglionic phenotype 
In summary, many of the genetic abnormalities seen in animal models are phenotypically similar or 
identical to human HSCR, and the human genes were predominantly discovered through studies 
of mice with similar defects who had either spontaneous or designed mutations 28, 29, 54, 55, 142. The 
most important of these genes code for molecules in the GDNF/RET signaling pathway, or the 
EDN3/EDNRB signaling pathway. These two signaling pathways have been identified as critical 
players in enteric neurogenesis. However, the genotype-phenotype relationship for genes involved 
in HSCR is not simple, and can only be understood with knowledge of the development of the ENS 
(see paragraph 1.3). 
GDNF/RET signaling pathway
This signaling pathway is of importance for subpopulations of both peripheral and central neurons, 
having been shown by in vitro and in vivo assays to promote survival of neurons, mitosis of neural 
progenitor cells, differentiation of neurons, and neurite extension. The main purpose of this signaling 
pathway is the migration of the ENS precursors into the foregut 143, 144. Experimental work with 
mice has demonstrated a high expression of Gdnf  in the stomach at embryonic day 9.0, when the 
precursors start to migrate into the foregut. This seems to attract the Ret positive precursor cells 
(i.e. the vagal neural crest cells). Through time the Gdnf expression increases in more posterior 
parts of the intestine, with highest expression in the cecum around E10.5 145. Using in vitro gut 
cultures, it was established that RET was essential for the GDNF-mediated migration. Disruption 
of this signaling pathway would thus influence the migrational behavior of the ENS precursors. 
Interestingly, only the distal part of the gut is aganglionic. This could indicate that as it is the last 
part to be reached, any disruption in migration would affect only the distal part of the intestine. 
In addition to its chemoattractive role in ENS development, GDNF has also been reported to 
be necessary for the proliferation and survival of ENS precursors 146, 147, processes that may be 
modulated by EDN3 148, 149 . 
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EDN3/EDNRB signaling pathway
EDN3 and its G-protein coupled receptor EDNRB are other important components of the signaling 
process, particulary in the development of the distal colon. EDN3 is expressed mainly in the cecum 
around E10.5, whereas its receptor EDNRB is expressed in the migratory ENS precursors. An 
interaction between the GDNF and the EDN3 signaling pathways has been demonstrated in both 
human and mouse 96, 150 Mice lacking Edn3 have an aganglionic gut, however reducing the signaling 
capacity of Ret results in an improved colonization of the hindgut, indicating a fine balance between 
the 2 signaling pathways 151. EDN3 has a role in inhibiting crest cell differentiation to ensure that 
sufficient ENS precursors are available to completely colonize the gut 148, 149. In spontaneous or 
targeted mutations affecting Edn3, the distal hindgut fails to be colonized by neural crest cells and 
remains aganglionic 28, 152, supporting the hypothesis that in the absence of Edn3, enteric precursors 
differentiate prematurely and therefore fail to colonize the entire length of the intestine. Furthermore 
it was shown that EDNRB modifies the migratory response of neural crest cells to GDNF 153.
ECE-1 plays a role in activating, amongst others, EDN3, thus enabling EDNRB signaling. 
ECE-1 is a protease that performs the second cleavage to generate functional EDN3. Impaired 
function of ECE1 may thus lead to impaired function of EDN3: similar abnormalities are found in 
mice lacking Ece-1, End3 or Ednrb 30. 
Transcription factors
Three transcription factors SOX10, PHOX2B and ZFHX1B are involved in syndromic HSCR (see 
previous paragraph). Sox10 encodes a transcription factor that can regulate expression of Ednrb 154 
and Ret 118. EDNRB has an enhancer element with binding sites for SOX10. Partial deletion of this 
enhancer results in mice that die postnatally from megacolon suggesting that the corresponding 
region in human EDNRB may be relevant to HSCR. It is therefore likely that mutations in SOX10 
result in misregulation of EDNRB, which will have an effect on the migration of the ENS precursors 
as well. The severity of the aganglionosis phenotype could be dependent on such interactions 155.
Phox2b is also a transcription factor, and is expressed in several classes of differentiating 
neurons of both the peripheral nervous system (including the ENS) and the central nervous system. 
Homozygous disruption of the Phox2b gene in mice results in the absence of all enteric ganglia, a 
clinical picture reminiscent of HSCR. Furthermore, Phox2b mutants do not show Ret expression and 
it has then been postulated that the PHOX2B gene may play a regulatory role in RET expression and 
account for the lack of enteric nervous system development in HSCR  156 118.
Finally ZFHX1B, a transcription modulator (a repressor of transcription) in the TGFβ 
signaling cascade , is expressed in early neural development in xenopus  157. Its exact role in HSCR 
pathogenesis is unknown, however a possible functional link between ZFHX1B and RET is suggested 
127. Studies in homozygous Zfhx1b mutant mice have shown a complete lack of vagal neural crest 
cells cell precursors reflecting the dependence of these precursors on Zfhx1b activity for their 
normal development  158.  
3. Aims and outline of the thesis
The preceding paragraphs discussed the history, etiology, pathogenesis and genetics of HSCR. This 
thesis will address the different aspects of the genetics of HSCR and, in particular, of the syndromic 
forms of HSCR. As discussed, the genetic studies of HSCR as a complex disorder shifted from 
family-based studies towards sib-pair and population-based studies. Despite the improvement in 
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the genetic analysis of HSCR patients following the discovery of 9 susceptibility genes, there remains 
a group of patients with histological proven HSCR that do not have a mutation in the currently 
known genes. Although it is shown that HSCR is oligogenic and that RET is involved in almost all 
cases 71, 74, additional HSCR loci and genes are likely to be identified in the future. However, finding 
these HSCR susceptibility loci and genes might turn out to be difficult. A single approach might 
not suffice. Studying families with rare presumptive single-gene associations of HSCR with other 
congenital abnormalities might be worthwhile. The genes involved in these syndromes might shed 
further light on the pathways underlying HSCR in general and may be useful in the understanding of 
the non-syndromic form of HSCR as well. 
From 1970 to1995, 239 consecutive children with HSCR were admitted at the Pediatric 
Surgery Department of the Erasmus MC/Sophia Children’s Hospital 159. A total of 71 children 
(30%) had additional anomalies, consistent with data from the literature 8, 10, 59. Chromosomal 
and monogenic syndromes were reported in 15 and 4 patients respectively. Fourteen males and 2 
females had trisomy 21. In one female patient a duplication of chromosome 11 was detected. Shah-
Waardenburg syndrome occurred in only two patients, a brother and a sister 97. Two sporadic cases 
had CCHS; one of them also had a neuroblastoma.  
The aim of our studies was to identify new genes involved in HSCR susceptibility by 
studying both non-syndromic and syndromic families, treated at the Pediatric Surgery Department 
of the Erasmus MC/Sophia Children’s Hospital. To this end we chose the traditional linkage study 
design. From the 239 consecutive HSCR patients, we selected 3 families to study in detail. 
In part 1, we characterized families in which HSCR segregates with additional congenital 
malformations. We performed phenotypic studies and DNA analyses. Our objectives were 1). to 
delineate the clinical features of Goldberg-Shprintzen syndrome in a consanguineous Moroccan 
family (chapter 2); 2). to identify the genetic defect in this family by homozygosity mapping (chapter 
3); 3). to prove that Goldberg-Shprintzen syndrome is not only clinically but also genetically different 
from Mowat-Wilson syndrome (chapter 3); 4). to perform clinical and molecular studies in additional 
families with Goldberg-Shprintzen syndrome  (chapter 4); 5). to characterize a family in which 
HSCR segregates with postaxial polydactyly and to discuss the differential diagnostic considerations 
(chapter 5). 
In part 2, we present a genome-wide linkage analysis of a non-syndromic HSCR family 
who did not have a RET mutation and identified suggestive linkage for a new HSCR susceptibility 
locus at 4q31.3-q32.3 (chapter 6).     
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Tables
Table 1 Current genes and loci involved in HSCR
Gene OMIM Map 
Position
Inheritance Phenotype
RET 164761 10q11.2 Dominant, incomplete 
penetrance
Non-syndromic
MEN2A
GDNF 600837 5p13 Non-Mendelian Non-syndromic
Neurturin 602018 19p13 Non-Mendelian Non-syndromic
EDNRB 131244 13q22 Recessive Shah-Waardenburg
ABCD
Dominant (de novo in 80%) Non-syndromic
EDN3 131242 20q13 Recessive Shah-Waardenburg
Dominant, incomplete 
penetrance
Non-syndromic
SOX10 602229 22q13 Dominant (de novo in 75%) Shah-Waardenburg
ECE-1 600423 1p36 De novo dominant Congenital heart 
malformation
ZFHX1B 605802 2q22 De novo dominant Mowat-Wilson 
PHOX2B 603851 4p12 Dominant (de novo in 90%) CCHS
Unknown 3p21 Non-Mendelian Non-syndromic, 
S-HSCR
Unknown 9q31 Dominant, incomplete 
penetrance
Non-Syndromic, 
L-HSCR
Unknown 19q12 Non-Mendelian Non-syndromic, 
S-HSCR
Unknown 16q23 Non-Mendelian Shah-Waardenburg
Table 2  Clinical features of syndromes with HSCR as a mandatory feature
Gene OMIM Syndrome Clinical Features
EDNRB 277580 Shah-Waardenburg Deafness, pigmentary abnormalities 
600501 ABCD Albinsm, black lock, cell migration disorder 
of the neurocytes of the gut (i.e.HSCR), 
and deafness
EDN3 277580 Shah-Waardenburg Deafness, pigmentary abnormalities
SOX10 277580 Shah-Waardenburg Deafness, pigmentary abnormalities, 
polyneuropathy
277580 Shah-Waardenburg and 
neurological features
Ataxia, leukodystrophy, demyelinating 
polyneuropathy, mental retardation 
PHOX2B 209880 Haddad  or
Ondine-Hirschsprung
Congenital Central Hypoventilation 
Syndrome, neuroblastoma, autonomic 
dysfunction 
ZFHX1B 235730 Mowat-Wilson Mental retardation, microcephaly, epilepsy, 
corpus callosum agenesis 
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Table 3 Oligogenic inheritance in HSCR
Genes/loci Phenotype Study design Ref
RET/ 3p21/ 19q12 Non-syndromic HSCR Linkage in an affected sib-pairs 
design    
74
EDNRB/ 16q23/ 
10q11.2
Shah-Waardenburg Association studies in trio-design in 
isolated population  
96
RET/ 9q31 Non-syndromic HSCR Classical linkage in multigenerational 
families 
71
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Abstract
Hirschsprung disease, mental retardation, microcephaly, and specific craniofacial dysmorphism 
were observed in three children from a large, consanguineous, Moroccan family. A fourth child 
showed similar clinical features, with the exception of Hirschsprung disease. The association of 
these abnormalities in these children represents the Goldberg-Shprintzen syndrome (OMIM 
235730). Mutation scanning of genes potentially involved in Hirschsprung disease, RET, GDNF, 
EDN3, and EDNRB, showed a sequence variant, Ser305Asn, in exon 4 of the EDNRB gene in the 
index patient of this family. The Ser305Asn substitution present in two of the four patients and 
four healthy relatives and absent in one of the remaining two patients illustrates the difficulties in 
interpreting the presence of mutations in families with Hirschsprung disease. It is unlikely that the 
EDNRB variant contributes to the phenotype. This consanguineous family might be useful for the 
identification of a Goldberg-Shprintzen locus.
Introduction 
Hirschsprung disease (HSCR) is a congenital disorder characterised by the absence of ganglion cells 
from the bowel wall. The estimated incidence is 1 in 5000 live born children. Boys are affected four 
times as often as girls. Additional anomalies, mostly of the heart and kidneys, occur in 10-30% 1, 
2. HSCR is a variable feature in a large number of monogenic syndromes, such as Waardenburg 
syndrome, cartilage-hair hypoplasia syndrome, Smith-Lemli-Opitz syndrome, Nager acrofacial 
dysostosis, Kaufman-McKusick syndrome, Bardet-Biedl syndrome, and primary hypoventilation 
syndrome (Ondine-Hirschsprung disease) 3-7. This variety of syndromes associated with HSCR 
implies considerable genetic heterogeneity in the aetiology of HSCR, although some of these 
syndromal associations may be through chance. 
 Traditionally, HSCR as an isolated entity is viewed as having a complex inheritance and 
being transmitted as a sex modified multifactorial trait. However, clear autosomal dominant and 
autosomal recessive inheritance have been reported 8. Mutations in five genes have been implicated 
in isolated or syndromic HSCR: RET,9, 10 which encodes a receptor tyrosine kinase and its ligand, 
glial cell line derived neurotrophic factor (GDNF),11, 12 EDNRB, the gene encoding the endothelin 
B receptor,13 and endothelin 3 (EDN3), one of its ligands 14, 15. Homozygous mutations in the latter 
two genes are associated with HSCR, pigmentary abnormalities, and deafness (Shah-Waardenburg 
syndrome). A similar phenotype is associated with heterozygous mutations in the SOX10 gene.16. 
RET mutations have been observed in approximately 50% of familial cases and 10-30% of sporadic 
cases. Mutations of EDNRB, EDN3, and GDNF have been reported in only a few cases 17. 
 Here we describe a syndrome consisting of HSCR, mental retardation, microcephaly, and 
dysmorphic features in four patients of a large, consanguineous, Moroccan family. These phenotypic 
features are consistent with Goldberg- Shprintzen syndrome. A rare EDNRB variant was found, not 
cosegregating with the phenotype.
Case reports
Patient VI.1 is the first daughter of a consanguineous Moroccan couple; their maternal grandmothers 
were sisters (fig 1). After premature rupture of the membranes, there was spontaneously delivery at 
40 weeks of gestation; her birth weight was 3280 g (50th centile) and occipitofrontal circumference 
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(OFC) 33 cm (3rd centile). She was admitted to our hospital because passing of meconium was 
delayed and she had feeding problems. Short segment HSCR was diagnosed. She had a temporary 
colostomy at 2 weeks of age and intestinal reconstruction at the age of 6.5 months.
At 2 weeks of age, she showed telecanthus (her ICD was 2.7 cm (>97th centile) and OCD 7 cm (75th-
97th centile)), a prominent nasal bridge, tapering fingers, and widely spaced nipples. Involuntary 
movements of the head started from 3 months of age. She was able to sit without support at the age 
of 7 months, but showed titubation of the head when seated or vertically suspended. An MRI scan 
of the brain at 9 months of age showed a slight general brain atrophy with delayed myelinisation. At 
2 years, she manifested the described dysmorphism, progressive microcephaly, mildly downward 
slanting palpebral fissures, a flat occiput, short philtrum, and large ears. At the age of 26 months, her 
development is retarded and is equivalent to a chronological age of 14 months.
 Patient V.4 was the second child of a consanguineous couple. The boy’s father (IV.3) is the 
brother of the maternal grandmother of the case described above. Pregnancy and delivery (at 38 
weeks) were uneventful. Birth weight was not recorded and OFC was 33.5 cm (3rd-10th centile). 
A broad nasal bridge, low set ears, and a short neck were reported. Failure to pass meconium 
and vomiting were indications for referral to the Department of Paediatric Surgery. Long segment 
HSCR was diagnosed and an ileostomy was made. He died from complications of sepsis at the age 
of 3 weeks. Necropsy was not permitted. He had a normal 46,XY karyotype.
 Patient V.6, a 12 year old girl, is the fourth child of this couple. She was born at term after an 
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Figure 1
Pedigree of family. Subjects with the Goldberg-Shprintzen phenotype are indicated by blackened symbols. Patients V1.1, V.4, and V.6 
have histologically proven Hirschsprung disease. V.9 has microcephaly, mental retardation, and characteristic facial abnormalities, 
but no Hirschsprung disease.  
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uneventful pregnancy. Her birth weight was 4000 g (50th-97th centile) and OFC was 33.5 cm (3rd-
50th centile). A lesion of the right inferior part of the brachial plexus or Erb-Duchenne palsy was 
noted. From 2 months of age, she developed progressive constipation, which prompted admission to 
our department. Her abdomen was distended. A barium enema was suggestive of HSCR. Absence 
of ganglion cells and increased acetylcholinesterase staining in nerve fibres were found at biopsy. A 
low anterior resection with a primary anastomosis was performed. The postoperative course was 
uncomplicated. 
 At the age of 5 months, the child neurologist saw her for suspected psychomotor retardation, 
microcephaly (OFC 39 cm, 3rd centile), and a mild convergent strabismus. BERA (brain stem evoked 
response audiometry) and VEP (visual evoked potential) showed no overt abnormalities. Brain CT 
at the age of 5 years showed a slight asymmetry of the lateral ventricles and a hypoplastic septum 
pellucidum. The karyotype was 46,XX. Dysmorphological evaluation at 5 years (fig 2) showed high 
arched eyebrows, dense curled eyelashes, a broad nasal bridge, blue sclerae, large corneae (corneal 
diameter 13.5 mm), a mild thoracic scoliosis, mild syndactyly of digits II and III, and a broad hallux.
She has mental retardation and a severe conductive hearing loss, related to therapy resistant middle 
ear infections. Follow up at 6, 8, and 11 years (fig 2) showed height following the 3rd centile and 
head circumference paralleling the 3rd centile. Progressive scoliosis and proximal muscle weakness 
were noted from 10 years of age. Lung function showed a strongly reduced vital capacity, not 
proportional to the severity of the kyphoscoliosis. Recurrent corneal infections suggested a primary 
corneal hypoaesthesia.
Figure 2
(Above) Patient V.6 at 5 years and 
12 years. Note hypertelorism and 
curled eyelashes and clouding of 
the cornea at the age of 12 years. 
(Below) Patient V.9 at 8 months 
and 7 years. Note hypertelorism, 
synophrys, and curled eyelashes. 
Clouding of the cornea is present.
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 The seventh child (V.9) was born after a healthy girl and boy. Caesarean section was 
indicated because of a transverse lie. His birth weight was 4115 g (90th centile). When he was 8 
months, the parents noticed developmental delay and remarkable physical resemblance to their 
older daughter (V.6) (fig 2). His OFC was 42 cm (<3rd centile). He had dense eyebrows with 
mild synophrys, a broad nasal bridge, low set ears, and large corneae (corneal diameter 14.5 mm) 
with blue sclerae. Hypotonia and slipping through on vertical suspension were present. At the 
age of 13 months his height was 75 cm (10th-25th centile), OFC 43 cm (2 cm <3rd centile), ICD 
3.2 cm (>97th centile), and OCD 8.8 cm (>97th centile). He had telecanthus, downward slanting 
palpebral fissures, broad nasal bridge with a bulbous nose, a high arched palate with a bifid uvula, 
and large anteverted ears. His thumbs were short and broad and his toes overlapped. He had 
corneal hypoaesthesia and recurrent corneal infections (fig 2). Defecation was reportedly normal. 
Brain imaging was not performed. Table 1 lists the phenotypic features of all four patients.
Table 1 Phenotypic features in four Goldberg-Shprintzen syndrome patients
Case 1 VI.1 Case 2 V.4 Case 3 V.6 Case 4 V.9
HSCR SS-HSCR TCA SS-HSCR No HSCR
Mental retardation + ? + +
Hypotonia + ? - -
Microcephaly + + + +
Brain scan Abnormal ? Abnormal ?
Arched,dense eyebrows + ? + +
Curled eyelashes + ? + +
Synophrys + ? + +
Hypertelorism + ? + +
Corneal ulcer - ? + +
Megalocornea ? ? + +
Wide nasal brigde + + + +
Bulbous nasal tip + ? + +
Anteverted ears + + + +
Bifid uvula - ? ? +
Toes Broad hallux Overlapping
Skeletal abnormalities - ? Scoliosis -
Ataxia of the head + ? - -
Karyotype 46, XX 46, XY 46, XX 46, XY
DNA analysis S305N ? - S305N
TCA=total colonic aganglionosis. SS-HSCR=short segment Hirschsprung disease. ?=not evaluated/
described. +=present.-=absent.
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Laboratory studies
All four patients appeared to have a normal karyotype.. DNA was isolated from leucocytes prepared 
according to standard methods. DGGE analysis of all exons of RET, GDNF, EDNRB, and EDN3 was 
performed on the index patient VI.1 as described before (RMW Hofstra and J Osinga)14, 18. Apart 
from known neutral variants, a similar mobility shift of exon 4 of EDNRB was detected in index 
patient VI.1 (fig 3). Sequencing showed a G to A transition that at the amino acid level results in the 
replacement of a serine by an asparagine (Ser305Asn). On screening 12 available family members 
(IV.2, IV.3, IV.4, V.1, V.2, V.3, V.5, V.6, V.7, V.8, V.9, and V.10), five (IV. 2, IV.3, V.2, V.7, and V.9) were 
found to be carriers of the EDNRB variant. The Ser305Asn substitution was not identified in 100 
(unselected) HSCR patients or 70 healthy Dutch controls (140 chromosomes). However, we did not 
genotype unrelated Moroccan subjects for this substitution.
Discussion
The dysmorphic features in these four patients closely resemble the syndrome described by 
Goldberg and Shprintzen 19 in 1981 and later by others 20-24. Common features in reported cases 
were microcephaly, mental retardation, distinctive face, and HSCR. Goldberg and Shprintzen 19 only 
reported submucous cleft palate. Coloboma of the iris was not always present 19, 20. An autosomal 
recessive mode of inheritance was suggested, based upon two sibs in one pedigree with unaffected 
parents and one consanguineous pedigree. This mode of inheritance is also most likely in our 
V
V I
V.1 V.2 V I.1
Figure 3
DGGE analysis of EDNRB exon 
4. PCR products were amplified 
from genomic DNA from patient 
VI.1 (lane 3), her father V.1 (lane 1), 
and mother V.2 (lane 2). A mobility 
shift was found in the patient and 
her mother. Sequencing of the PCR 
products showed the Ser305Asn 
substitution. Both mother and patient 
are heterozygous.
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consanguineous pedigree. This syndrome should not be confused with the Shprintzen-Goldberg 
syndrome (OMIM 182212, craniosynostosis, marfanoid habitus). 
 The neurological abnormalities seen in our patients have not been reported before. 
They might either belong to the clinical spectrum of Goldberg-Shprintzen syndrome, occurring 
at a later stage, or be caused by another autosomal recessive trait segregating in this family from 
a common ancestor. This second trait could cause proximal muscle weakness, hypotonia, and 
the eye abnormalities. Kim et al 25 recently reported a similar phenotype in a 15 year old boy 
with microcephaly, mental retardation, a characteristic face, HSCR, proximal muscle weakness, 
cerebellar dysfunction, and scoliosis. The parents were not consanguineous. His brother had mild 
developmental delay and a paternal cousin had isolated HSCR. 
 The eye abnormalities (megalocorneae and corneal hypoaesthesia) in two out of four 
patients have not been reported previously in Goldberg-Shprintzen syndrome. Their differential 
diagnosis includes megalocornea-mental retardation or MMR syndrome (OMIM 249310) 26. HSCR 
and mild microcephaly was described once in combination with familial dysautonomia (OMIM 
223900) 27. Both syndromes can be excluded in our patients. Thus we propose that the Goldberg-
Shprintzen syndrome can be associated with neurological and ophthalmic symptoms at a later age.
A causative role for the Ser305Asn EDNRB variant?
Among causative mutations involved in HSCR, 10 were reported to be in the EDNRB gene. They 
occurred predominantly in sporadic cases and were located in the transmembrane spanning 
domains 28-30 . The Ser305Asn substitution was previously reported by Auricchio et al 31 as a 
causative mutation in a sporadic Italian male patient with isolated HSCR. Biochemical data showed 
that in cows Serine305 is involved in post-translational modification (that is, phosphorylation) of the 
Ednrb protein 32. Therefore, substitutions of this amino acid might have functional consequences, 
resulting in HSCR. The Ser305Asn substitution cannot explain the Goldberg-Shprintzen phenotype 
by itself since it does not cosegregate with the phenotype (for example, while V.6 is affected with 
Goldberg-Shprintzen syndrome, but does not have the EDNRB variant, the reverse applies to 
V.7). The most likely explanation for the phenotype in this consanguineous family seems to be 
homozygosity for a mutation in a presumed Goldberg-Shprintzen gene; none of the patients in this 
family was found to be homozygous for the Ser305Asn substitution. Although we do not know the 
frequency of Ser305Asn substitutions in the Moroccan population, it is unlikely that the EDNRB 
variant contributes to the phenotype in our family. This family might be instrumental in identifying a 
Goldberg-Shprintzen gene. The presence of a mutation in the EDNRB gene in this family illustrates 
the difficulties in interpreting the presence of mutations in families with HSCR 33.
 Although the function and interactions of the multiple HSCR susceptibilty genes await 
further clarification, mutation analysis in syndromic HSCR patients might offer insight into the 
pleiotropic effects of these genes. Detailed dysmorphological evaluation of syndromic HSCR 
patients may give clues as to additional susceptibility genes for HSCR.
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Summary 
We identified, by homozygosity mapping, a novel locus on 10q21.3-q22.1 for Goldberg-Shprintzen 
syndrome (GOSHS) in a consanguineous Moroccan family. Phenotypic features of GOSHS in this 
inbred family included microcephaly and mental retardation, which are both central nervous system 
defects, as well as Hirschsprung disease, an enteric nervous system defect. Furthermore, since 
bilateral generalized polymicrogyria was diagnosed in all patients in this family, this feature might 
also be considered a key feature of the syndrome. We demonstrate that homozygous nonsense 
mutations in KIAA1279 at 10q22.1, encoding a protein with two tetratrico peptide repeats, underlie 
this syndromic form of Hirschsprung disease and generalized polymicrogyria, establishing the 
importance of KIAA1279 in both enteric and central nervous system development.
Goldberg-Shprintzen syndrome (GOSHS)1, 2 is a disorder characterized by microcephaly, mental 
retardation, facial dysmorphism, and Hirschsprung disease (HSCR). GOSHS shares the same 
accession number (MIM 235730) in the Online Mendelian Inheritance in Man (OMIM) database as 
the  comparable disorder named Mowat-Wilson syndrome (MWS) 2. Genetically, however, they are 
different. MWS occurs as a de novo dominant syndrome; whereas GOSHS is most likely inherited as 
an autosomal recessive trait, a hypothesis based on the occurrence of the disease in consanguineous 
pedigrees and in affected sibs with unaffected parents 3, 4. MWS is associated with de novo mutations 
in ZFHX1B located at 2q22 5-7, whereas, for GOSHS, no causative gene has yet been identified. Also, 
some clinical differences exist. In patients with MWS, neurological abnormalities such as epilepsy (in 
a high percentage), agenesis of the corpus callosum (in 35% of patients), and cortical malformations 
(in a minority of  patients) have been reported 5, 7, 8. In the few patients with GOSHS discussed in 
published reports, neurological symptoms have not been studied in detail, and the cause of the 
microcephaly and mental retardation remains obscure 1, 3.
Here, we describe a family with HSCR (an anomaly of the enteric nervous system that 
is of neural crest origin and is histologically characterized by the absence of ganglion cells in the 
myenteric and submucosal plexuses) 9 as a variable feature and bilateral generalized polymicrogyria 
(PMG) (a developmental malformation of the cerebral cortex, characterized by an enlarged number 
of smaller convolutions or gyri and disruption of the normal six-layered cerebral cortical structure) 
10 as a constant feature. The established diagnosis for this family was GOSHS, although bilateral 
generalized polymicrogyria (BGP) has not been reported as part of the syndrome before. 
To unravel the genetic basis of GOSHS, we performed a complete genome scan and 
homozygosity mapping in a large consanguineous Moroccan family reported elsewhere 4. The 
segregation of the disease in the pedigree is consistent with an autosomal recessive mode of 
inheritance, with several consanguineous loops (fig 1), and the family therefore was considered 
suitable for homozygosity mapping 11. 
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Figure 1 Pedigree structure and haplotypes of the Moroccan family with GOSHS. Patients are represented as blackened symbols. 
The shared region of homozygosity (red) in all affected cases is delimited by markers CGR166 and GCR170.Six of the 11 markers typed 
for refining the candidate region between marker D10S1652 and D10S537 are shown.
Informed consent was obtained from the parents of all subjects. In this family, five patients had the 
cardinal signs characterizing GOSHS (one boy lacked HSCR). One child with long-segment HSCR 
died in the neonatal period; his DNA was unavailable for our study. When the youngest patient was 
diagnosed, brain magnetic resonance imaging (MRI) revealed BGP. MRI scans of all living patients 
also revealed BGP (fig 2). Gait disturbance, speech defect, excessive drooling, and pseudobulbar 
signs indicate diffuse cortical dysfunction including the perisylvian areas. 
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Figure 2
Representative MRIs of patient VI-1 (panels A and B) and patient VI-10 (panels C and D) showing BGP. A, Axial T2- weighted MRI of 
patient VI-1 at age 5 mo, showing frontoparietal and occipital bilateral PMG. B, Coronal FLAIR image of the same patient showing 
perisylvian PMG (arrow). C, T1-weighted axial image of patient VI-10 at age 14 years, showing BGP with distribution similar to that 
seen in patient VI-1. D, Parasagittal T1-weighted image of patient VI-10, showing PMG of the right peri-insular temporal lobe. 
Genomic DNA was isolated from peripheral leukocytes by use of the method described by Miller 
et al. 12. By haplotyping, FISH, and sequence analyses, we excluded the ZFHX1B gene as a cause of 
GOSHS in this family (data not shown). For the systematic genome scan, 381 markers (STRPs) from 
the ABI Prism Linkage Mapping Set MD-10 (version 2.5), with an average spacing of 10cM, were 
tested. DNA amplification was performed using 25 ng genomic DNA in 7.5- µl PCRs containing 
1xPCR Gold Buffer, 2.5 mM MgCl
2
, 10 µM primer pair mix, and 0.4 U AmpliTaq Gold DNA polymerase 
(Applied Biosystems). Amplification conditions were 10 min at 95°C, followed by 35 cycles of 30 s at 
95°C, 30 s at 55°C, and 1 min 30 s at 72°C; amplification was ended by a final extension for 5 min at 
72°C. PCR products were pooled in panels and loaded on an ABI 3100 automated sequencer. Data 
were analyzed using GeneMapper software (version 2.1) (Applied Biosystems).  
After this initial screening a region on 10q21.3-q22.1 was further investigated, since one of 
the four affected individuals was homozygous by descent for two consecutive markers, D10S1652 
and D10S537, whereas the other three patients were homozygous for one of these two markers. No 
other regions of homozygosity for consecutive markers were identified. We saturated the region 
between markers D10S1652 and D10S537 (12.3 cM) with 11 additional markers; they either were 
obtained from the Marshfield genetic map (Center for Medical Genetics Website) or were newly 
developed. Marker order and genetic distances were obtained from the Marshfield genetic map 
(Center for Medical Genetics Website) and the Celera physical map. All patients were homozygous 
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for 7 of these 11 markers. A recombination event between loci CGR166 and CGR167 in patient VI-7 
defined the centromeric boundary of the genetic interval. The telomeric border was defined by 
recombination events between markers D10S1665 and CGR170 in patients VI-1 and VI-3 (fig 1). 
These recombination events reduced the candidate region to a minimum of 2.8 Mb and a maximum 
of 3.8 Mb. 
Parametric two-point and multipoint linkage analyses were performed using MLINK 
program from the LINKAGE (version 5.1) software package 13 and SimWalk2 program (version 
2.9) 14. LOD scores were calculated, under the assumption that the disease phenotype is a rare 
autosomal recessive disorder with 100% penetrance, with a gene frequency of 1:5000. No 
phenocopies were allowed, and equal allele frequencies were used because of the limited number of 
available independent family members. A significant two-point LOD score was obtained (maxLOD 
score 3.29 and θ=0 for marker CGR167) (table 1); which increased to a maximum multipoint LOD 
score of 5.9 between markers CGR167 and D10S1647 (fig 3). 
Table 1
Results of two-point LOD score analysis, performed for markers used in fine mapping
LOD at θ=0
Markera 0 .01 .05 .1 .2 .3 .4
D10S196 -13.81 -3.96 -1.52 -.65 -.08 .02 0
D10S1652 -6.96 -2.39 -1.85 -1.36 -.68 -.35 -.15
D10S1743 -4.97 1 1.39 1.31 .9 .46 .14
CGR166 -3.7 .58 1.03 1.02 .73 .4 .13
CGR167 3.29b 3.21 2.9 2.51 1.73 1 .4
D10S210 2.59 2.53 2.26 1.92 1.26 .67 .24
D10S1678 1.49 1.45 1.29 1.09 .72 .4 .16
D10S1647 1.84 1.79 1.58 1.33 .86 .47 .19
D10S1672 2.88 2.81 2.52 2.15 1.42 .76 .25
D10S1665 2.77 2.7 2.43 2.08 1.39 .75 .25
CGR172 1.36 1.32 1.17 .97 .62 .32 .11
CGR170 -.28 1.59 1.97 1.88 1.4 .83 .33
D10S676 -.28 1.25 1.64 1.56 1.1 .59 .18
D10S537 -.11 1.45 1.82 1.71 1.2 .65 .21
a Marker order follows that of the Celera physical map.
b Max LOD score.
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The maximum 3.8-Mb linked region of shared homozygosity (defined by CGR166 and CGR170) 
contained in total 25 known genes and 5 genes encoding hypothetical proteins, in accordance with 
the National Center for Biotechnology Information (NCBI) build 34 of the human genome and the 
Ensemble Genome Browser. We first sequenced seven functional candidate genes on the basis 
of their putative involvement in neurogenesis (CTNNA3, LRRTM3, ATOH7, DDX50, DDX21, NET-7 
and NEUROG3), either using cDNA obtained by RT-PCR from a lymphoblastoid cell line of patient 
VI-10 and from a control or using genomic DNA from both. Mutations were not identified. We 
then performed a systematic mutational screening of all transcripts from the candidate region. 
PCR products from either genomic DNA (exons including flanking intronic sequences) or reverse- 
transcribed products (ORFs) were amplified and purified (ExoSapit [USB]). PCR primers, which were 
designed using standard software (Primer3), and conditions are available on request. Bidirectional 
sequencing was performed using BigDye Terminator chemistry on an ABI 3100 sequencer (Applied 
Biosystems). With the use of the software package SeqScape (version 2.1) (Applied Biosystems), 
sequences were aligned and compared with consensus sequences. 
Analysis of 98% of all coding sequences from the region revealed one likely disease-causing 
homozygous nucleotide substitution, 303C→T, in exon 1 of the KIAA1279 gene (fig 4A). This 
transversion leads, at the amino acid level, to a replacement of an arginine by a stop codon 
(R90X), resulting in a shortened protein of 89 amino acids. The 303C→T mutation showed 
complete segregation with the disease in the family. One hundred ethnic matched control 
chromosomes (of North African origin) were screened for the R90X mutation, and none of the 
controls carried this mutation. Subsequently, one additional family of British Pakistani ancestry, 
with a similar phenotype to that found in the Moroccan family, was screened for mutations 
in this gene. This family had four affected individuals with multiple inbreeding loops. Clinical 
characteristics were consistent with GOSHS, and CT brain scans of this family were described 
in a previous study and were thought to represent an abnormality of neuronal migration 3. In the 
affected individuals, a homozygous G→T transversion was identified at nt 285, resulting, at the 
amino acid level, in the replacement of a glutamic acid with a stop codon (E84X)(fig 4B). Two 
different homozygous nonsense mutations in KIAA1279 in two independent families with GOSHS 
strongly indicate that KIAA1279 is the gene responsible for GOSHS.
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Figure 3  
Multipoint LOD score analysis 
across and beyond the region 
of homozygosity, flanked by 
markers D10S1652 and CGR170, 
with a peak LOD score of 5.9.
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KIAA1279 consists of seven exons spanning 28 kb of genomic DNA. The transcript encodes a protein 
of 621 aa. We identified orthologs of human KIAA1279 in fruit fly, frog, rat, mouse, bee, chicken, 
and Japanese puffer fish, using BLAST comparison (NCBI Web site). There is strong sequence 
conservation during evolution; the protein sequence of human KIAA1279 shares 89% amino acid 
identity with mouse product, 88% with rat product and 29% with fruit fly product. Multitissue 
northern blots (both adult and fetal) (fig 5) showed ubiquitous expression of the 2.4-kb KIAA1279 
mRNA without a specific pattern, with expression lacking only in blood leukocytes (fig 5A). In 
addition, northern blot hybridization identified KIAA1279 mRNA molecules in different parts of the 
adult CNS,-namely cerebellum, cortex, medulla, spinal cord, occipital lobe, frontal lobe, temporal 
lobe, and putamen (fig 5B). 
Figure 4
Mutations of KIAA1279 associated with GOSHS. A, Electropherogram of the mutation identified in the Morrocan family. The 303C→T 
mutation causes the replacement of an arginine with a stop codon (R90X) in exon 1. B, Electropherogram of the mutation identified in 
Pakistani family. A homozygous G→T transversion at nt 285, results in the replacement of a glutamic acid with a stop codon (E84X) 
in the patients.  
Figure 5
Expression of KIAA1279 in human adult and fetal tissues. A, Multi-tissue northern blots, incubated with a KIAA1279 probe, showing 
ubiquitous expression without a specific pattern (note the lack of expression in blood leukocytes). B, Northern blots from adult brain 
tissues, incubated with a KIAA1279 probe. C, Human fetal multi-tissue northern blot, showing widespread expression.
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This widespread KIAA1279 expression is consistent with data available in gene expression databases 
such as the Gene Expression Omnibus, the human Unidentified Gene-Encoded (HUGE) Protein 
Database, and the University of California-Santa Cruz (USCS) Genome Browser. The function of 
KIAA1279 is unknown. Neither the gene nor its derived protein shows any significant sequence 
similarity to known human cDNA or protein sequences. Possible aspects of the molecular function 
of KIAA1279 may be gleaned from its primary sequence. We predicted protein motifs and domains 
using the program SMART (Simple Modular Architecture Research Tool). The predicted protein 
contains two tetratrico peptide repeats (TPRs), which are structural motif consisting of 34 amino 
acid residues, in exon 1/2 and exon 4, respectively. Because of these repeats KIAA1279, may be 
considered a member of the TPR protein family 15. The most basic function of TPR motifs is to 
mediate protein-protein interactions. Proteins with TPR motifs are involved in a variety of biological 
processes, such as cell-cycle regulation, transcriptional control, mitochondrial and peroxisomal 
protein transport, neurogenesis and protein folding. Several diseases have been described as being 
caused by mutations in genes encoding proteins containing TPR domains- for example,
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Mutations of KIAA1279 associated with GOSHS. A, Electropherogram of the mutation identified in the Morrocan family. The 303C→T 
mutation causes the replacement of an arginine with a stop codon (R90X) in exon 1. B, Electropherogram of the mutation identified in 
Pakistani family. A homozygous G→T transversion at nt 285, results in the replacement of a glutamic acid with a stop codon (E84X) 
in the patients.  
Figure 5
Expression of KIAA1279 in human adult and fetal tissues. A, Multi-tissue northern blots, incubated with a KIAA1279 probe, showing 
ubiquitous expression without a specific pattern (note the lack of expression in blood leukocytes). B, Northern blots from adult brain 
tissues, incubated with a KIAA1279 probe. C, Human fetal multi-tissue northern blot, showing widespread expression.
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Leber congenital amaurosis (AIPL1) 16 and Charcot-Marie-Tooth type 4C neuropathy (KIAA1985) 17.
Since mutations in KIAA1279 are associated with HSCR and PMG, its protein product may play 
a pivotal role in both peripheral and central nervous system development. PMG is traditionally 
classified as a result of a disruption such as fetal hypoxic-ischemic damage, infection or exposure to 
toxic drugs in the second trimester (13-21 weeks) 18, 19. However, the identification of KIAA1279 as the 
GOSHS gene underlines the importance of genetic factors in the etiology of this neuronal migration 
disorder of the cortex, as was already proven 20 21 or suggested 22 23 for other forms of PMG. Under 
the assumption that the main function of KIAA1279 is to bind other proteins, these target peptides 
might be (known) HSCR- or PMG- associated susceptibility factors. More likely, however, these 
targets might play a more general role in neuronal development, since a malformation of cortical 
organization is a constant feature in the Moroccan family, whereas HSCR is a variable feature. 
Elucidation of KIAA1279 function, and more important, studies of KIAA1279 expression and protein 
interactions may provide new insight into the molecular basis of PMG and HSCR. 
Acknowledgments
We thank the patients and their families, for their support and the willingness to donate samples; 
Jeannette Hoogeboom and Martijn Breuning, for patient care; Jim Barkovich, for help with 
classification of PMG; Martinus Niermeijer, for his guidance; Elisabeth Lodder and Peter van der 
Spek, for bioinformatics support; Herma van der Linde and Erik Simons, for technical assistance; 
and Tom de Vries Lentsch, for help with preparation of the figures. This work was funded, in part, 
by Nederlandse organisatie voor Wetenschappelijk Onderzoek grants 901-04-210 and 901-04-225 
(to R.M.W.H.).
Web resources
Accession numbers and URLs for data presented herein are as follows:
Celera, http://www.celeradiscoverysystem.com/
Center for Medical Genetics, Marshfield Clinic Research Foundation, http://research.marshfieldclinic.
org/genetics/ 
Ensembl Genome Browser, http://www.ensembl.org/
GenBank, http://www.ncbi.nlm.nih.gov/GenBank/ (for CGR170 [accession number BV212295], 
CGR167[accession number BV 212296], CGR166 [accession number BV212297], D10S196 [accession 
number Z16598], D10S1652 [accession number Z52339], D10S1743[accession number Z53951], 
D10S210 [accession number Z16813], D10S1678 [accession number Z52660], D10S1647 [accession 
number Z52188]
Gene Expression Omnibus, http://www.ncbi.nlm.nih.gov/geo/ 
Human Unidentified Gene-Encoded Proteins database, http://www.kazusa.or.jp/huge/ 
NCBI, http://www.ncbi.nlm.nih.gov/ 
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm.nih.gov/OMIM/(for GOSHS 
and MWS) 
Primer3,http://frodo.wi.mit.edu/cgi-bin/primer3_www.cgi
SMART,http://smart.embl-heidelberg.de/. 
UCSC Genome Browser, http://genome.ucsc.edu/. 
593
KIAA1279 MUTATIONS IN GOSHS
References
1. Goldberg RB, Shprintzen RJ. Hirschsprung megacolon and cleft palate in two sibs. J Craniofac Genet Dev 
Biol 1981;1:185-9.
2. Mowat DR, Croaker GD, Cass DT, Kerr BA, Chaitow J, Ades LC, Chia NL, Wilson MJ. Hirschsprung 
disease, microcephaly, mental retardation, and characteristic facial features: delineation of a new syndrome 
and identification of a locus at chromosome 2q22-q23. J Med Genet 1998;35:617-23.
3. Hurst JA, Markiewicz M, Kumar D, Brett EM. Unknown syndrome: Hirschsprung‘s disease, microcephaly, 
and iris coloboma: a new syndrome of defective neuronal migration. J Med Genet 1988;25:494-7.
4. Brooks AS, Breuning MH, Osinga J, vd Smagt JJ, Catsman CE, Buys CH, Meijers C, Hofstra RM. A 
consanguineous family with Hirschsprung disease, microcephaly, and mental retardation (Goldberg-
Shprintzen syndrome). J Med Genet 1999;36:485-9.
5. Amiel J, Espinosa-Parrilla Y, Steffann J, Gosset P, Pelet A, Prieur M, Boute O, Choiset A, Lacombe D, Philip 
N, Le Merrer M, Tanaka H, Till M, Touraine R, Toutain A, Vekemans M, Munnich A, Lyonnet S. Large-
scale deletions and SMADIP1 truncating mutations in syndromic Hirschsprung disease with involvement 
of midline structures. Am J Hum Genet 2001;69:1370-7.
6. Wakamatsu N, Yamada Y, Yamada K, Ono T, Nomura N, Taniguchi H, Kitoh H, Mutoh N, Yamanaka T, 
Mushiake K, Kato K, Sonta S, Nagaya M. Mutations in SIP1, encoding Smad interacting protein-1, cause a 
form of Hirschsprung disease. Nat Genet 2001;27:369-70.
7. Zweier C, Albrecht B, Mitulla B, Behrens R, Beese M, Gillessen-Kaesbach G, Rott HD, Rauch A. “Mowat-
Wilson” syndrome with and without Hirschsprung disease is a distinct, recognizable multiple congenital 
anomalies-mental retardation syndrome caused by mutations in the zinc finger homeo box 1B gene. Am J 
Med Genet 2002;108:177-81.
8. Silengo M, Ferrero GB, Wakamatsu N. Pachygyria and cerebellar hypoplasia in a patient with a 2q22-q23 
deletion that includes the ZFHX1B gene. Am J Med Genet A 2004;127:109.
9. Okamoto E, Ueda T. Embryogenesis of intramural ganglia of the gut and its relation to Hirschsprung’s 
disease. J Pediatr Surg 1967;2:437-43.
10. Friede RL. Developmental neuropathology, 2 ed. Berlin: Springer Verlag, 1989.
11. Lander ES, Botstein D. Homozygosity mapping: a way to map human recessive traits with the DNA of 
inbred children. Science 1987;236:1567-70.
12. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human 
nucleated cells. Nucleic Acids Res 1988;16:1215.
13. Lathrop GM, Lalouel JM. Easy calculations of lod scores and genetic risks on small computers. Am J Hum 
Genet 1984;36:460-5.
14. Sobel E, Papp JC, Lange K. Detection and integration of genotyping errors in statistical genetics. Am J Hum 
Genet 2002;70:496-508.
15. D’Andrea LD, Regan L. TPR proteins: the versatile helix. Trends Biochem Sci 2003;28:655-62.
16. Sohocki MM, Bowne SJ, Sullivan LS, Blackshaw S, Cepko CL, Payne AM, Bhattacharya SS, Khaliq S, Qasim 
Mehdi S, Birch DG, Harrison WR, Elder FF, Heckenlively JR, Daiger SP. Mutations in a new photoreceptor-
pineal gene on 17p cause Leber congenital amaurosis. Nat Genet 2000;24:79-83.
17. Senderek J, Bergmann C, Stendel C, Kirfel J, Verpoorten N, De Jonghe P, Timmerman V, Chrast R, 
Verheijen MH, Lemke G, Battaloglu E, Parman Y, Erdem S, Tan E, Topaloglu H, Hahn A, Muller-Felber W, 
Rizzuto N, Fabrizi GM, Stuhrmann M, Rudnik-Schoneborn S, Zuchner S, Michael Schroder J, Buchheim 
E, Straub V, Klepper J, Huehne K, Rautenstrauss B, Buttner R, Nelis E, Zerres K. Mutations in a gene 
encoding a novel SH3/TPR domain protein cause autosomal recessive Charcot-Marie-Tooth type 4C 
neuropathy. Am J Hum Genet 2003;73:1106-19.
18. Barth PG, van der Harten JJ. Parabiotic twin syndrome with topical isocortical disruption and gastroschisis. 
Acta Neuropathol 1985;67:345-9.
19. Barth PG. Fetal disruption as a cause of neuronal migration defects. In: Barth PG, ed. Disorders of neuronal 
migration. London: MacKeith Press, 2003.
20. Piao X, Hill RS, Bodell A, Chang BS, Basel-Vanagaite L, Straussberg R, Dobyns WB, Qasrawi B, Winter 
RM, Innes AM, Voit T, Ross ME, Michaud JL, Descarie JC, Barkovich AJ, Walsh CA. G protein-coupled 
receptor-dependent development of human frontal cortex. Science 2004;303:2033-6.
60 3
21. Mitchell TN, Free SL, Williamson KA, Stevens JM, Churchill AJ, Hanson IM, Shorvon SD, Moore AT, van 
Heyningen V, Sisodiya SM. Polymicrogyria and absence of pineal gland due to PAX6 mutation. Ann Neurol 
2003;53:658-63.
22. Ciardo F, Zamponi N, Specchio N, Parmeggiani L, Guerrini R. Autosomal recessive polymicrogyria with 
infantile spasms and limb deformities. Neuropediatrics 2001;32:325-9.
23. Chang BS, Piao X, Giannini C, Cascino GD, Scheffer I, Woods CG, Topcu M, Tezcan K, Bodell A, Leventer 
RJ, Barkovich AJ, Grant PE, Walsh CA. Bilateral generalized polymicrogyria (BGP): a distinct syndrome of 
cortical malformation. Neurology 2004;62:1722-8.
614
CHAPTER 4
CLINICAL AND MOLECULAR STUDIES IN GOLDBERG-
SHPRINTZEN SYNDROME
Clinical and molecular studies in Goldberg-Shprintzen syndrome 
Alice S. Brooks, Jan Osinga, Grzegorz M. Burzynski, Kristi Jones, Meredith Wilson, Helen 
Murphy, Ian Ellis, Robert J. Shprintzen, Jane A. Hurst, Carole McKeown, Christiane Zweier, 
Anita Rauch, Michel Goossens, Koen Devriendt, Maarten Lequin, Patrick J. Willems, Ben A. 
Oostra, Grazia M.S. Mancini, Robert M.W. Hofstra
Manuscript in preparation

634
CLINICAL AND MOLECULAR STUDIES IN GOSHS
Abstract
In order to establish the phenotypic spectrum of Goldberg-Shprintzen syndrome (GOSHS), we 
studied 3 new GOSHS families including the original siblings described by Goldberg and Shprintzen. 
GOSHS is characterized by Hirschsprung disease, mental retardation, microcephaly, and a typical 
facial dysmorphism. MRI studies showed polymicrogyria in the proband of one of these families, and 
a simplified gyral pattern in one of the original GOSHS patients, indicating that malformations of 
cortical development are part of the clinical spectrum of GOSHS. 
In all three families novel truncating recessive KIAA1279 mutations were identified. To study the 
involvement of KIAA1279 in phenotypes related to GOSHS, we also screened 14 individuals (12 
sporadic cases, and 2 sibs) that were initially considered as possible Mowat-Wilson syndrome 
cases, a related syndrome with Hirschsprung disease-mental retardation-microcephaly, in whom 
mutations of the Mowat-Wilson syndrome gene ZFHX1B had been excluded. Furthermore, we 
studied KIAA1279 in a group of 26 sporadic, non-syndromic Hirschsprung disease cases, and 6 cases 
with isolated diffuse polymicrogyria. In none of these 3 groups, however, KIAA1279 mutations could 
be identified, indicating that KIAA1279 mutations specifically lead to GOSHS. Finally, additional genes 
for the combination of Hirschsprung disease with mental retardation and microcephaly are likely to 
exist, since not all cases can be attributed to mutations in either KIAA1279 or ZFHX1B.
Introduction   
Goldberg-Shprintzen syndrome or Goldberg-Shprintzen megacolon syndrome (GOSHS) (MIM 
609460), is a rare autosomal recessive syndrome with 6 families described in the literature 1-6. 
GOSHS presents with Hirschsprung disease (HSCR), microcephaly and moderate mental retardation 
1, 2. Distinctive associated facial features include high-arched eyebrows, synophrys, hypertelorism, 
cleft palate/bifid uvula, and clouding of the cornea related to a primary hypoesthesia of the cornea 
1, 6. Furthermore, an occasional patient with GOSHS is diagnosed with a congenital heart defect 5, 
or develops a progressive scoliosis starting in late childhood or early adolescence 1, 6. The eldest 
patients described in the literature are the 2 original cases reported by Goldberg and Shprintzen 
(respectively 13.5 years old and 10 years old at the time of publication), and case V.6 (age 12 years) 
previously reported by us in a Moroccan family.1, 6 HSCR proved to be a variable feature in GOSHS 
patients 5, 6. Both short segment HSCR and long segment HSCR have been described in GOSHS 6. 
Most patients with documented brain MRI were diagnosed with polymicrogyria (PMG) 7, and this 
clinical feature might be a key feature of GOSHS. Recently we identified the gene causing GOSHS 
as KIAA1279, a gene located at 10q22.1 and encoding a hypothetical protein with 2 tetratrico peptide 
repeats. GOSHS patients were shown to have inactivating homozygous KIAA1279 mutations 7.
GOSHS shows some clinical overlap with Mowat-Wilson syndrome (MWS) (OMIM 235730) 
8, which is characterized by uplifted ear lobes, hypertelorism, a pointed chin and is associated with 
de novo mutations in ZFHX1B located at 2q22 9 10-13. Recently, however, sib recurrence is described 
in MWS consistent with a germline mosaicism in one of the parents 13, 14. The clinical distinction 
between these two entities might be difficult in the young sporadic HSCR patient with microcephaly 
and mental retardation; several MWS cases have been initially misdiagnosed as GOSHS 15-18.  Most 
typically the shape and position of the eyebrows differ; i.e. horizontal, wedge-shaped eyebrows in 
MWS 11 and arched eyebrows that may cross the midline (synophrys) in GOSHS 1 2, 6.
To further delineate the phenotypic spectrum of GOSHS and to study which phenotypic 
features are associated with mutations in KIAA1279, we analysed 5 patients (from 3 families) with 
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clinical features of GOSHS, including the 2 original sibs described by Goldberg and Shprintzen in 
19811. Furthermore, we studied a group of 14 cases with presumptive MWS, 26 sporadic HSCR 
patients, and 6 cases with bilateral diffuse polymicrogyria, in order to assess the involvement of 
KIAA1279 in these cases.
Patients and Methods
GOSHS patients 
Three families were considered as having GOSHS. The first family was the original family with 
GOSHS consisting of 2 affected sibs (US1 and US2) reported by Goldberg and Shprintzen 1. Two 
additional GOSHS families were selected that were not described previously. As major inclusion 
criteria for GOSHS in our study the following features were used: i) HSCR of variable length, ii) 
facial dysmorphism (high arched eyebrows, synophrys, a high nasal bridge, hypertelorism), iii) small 
head circumference or microcephaly (defined as an occipito-frontal circumference or OFC< 3rd 
percentile), and iv) psychomotor retardation (Table 1). 
DNA was available from 5 patients; from family 1 (US1 and US2), family 2 (CYP1), and family 3 (UK1 
and UK2). Informed consent was obtained from the parents of the patients.
Table 1. Most prominent features of the three new GOSHS families, and the two previously 
described families with documented KIAA1279 mutations
Family Patient Sex MR Micro
Cephaly
Seizures HSCR Facial 
dysmorphism
Other Ref
1 US1 M + + - + + Scoliosis, 
simplified gyral 
pattern
1,This 
study
1 US2 F + + - + + Scoliosis, corneal 
transplants, cleft 
palate
1,This 
study
2 CYP1 M ND + - + + diffuse PMG This study
2 CYP2 F + ND - - + Scoliosis, leg 
muscle weakness
This study
3 UK1 M + + + + + This study
3 UK2 M + + - + + ASD, submucous 
cleft palate 
This study
4 Case 1 M + + - + + Scoliosis 2
4 Case 2 M + + - + + Iris coloboma 2
4 BP1 F + + - + + VUR This study
4 BP2 F + + - - + This study
5 V-4 M ND - - + + 6
5 V-6 F + + - + + Scoliosis, corneal 
transplants, 
diffuse PMG
6
5 V-9 M + + - - + Scoliosis, corneal 
transplants, bifid 
uvula, diffuse 
PMG
6
5 VI-1 F + + - + + Diffuse PMG 6
5 V1-3 F + + - + + Difuse PMG 7
ND: not documented. MR: psychomotor retardation; HSCR: Hirschsprung disease; PMG: polymicrogyria; 
VUR: vesicoureteral reflux
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MWS-like patients
We also sequenced the KIAA1279 gene in 14 cases (8 males, 6 females) which were considered as 
presumptive/possible MWS cases. This included 4 patients previously described by Zweier et al. as 
belonging to either group 2 having an ambiguous facial Gestalt of Mowat-Wilson syndrome (patients 
Erl1and Erl7), or to group 3 displaying a non-specific facial phenotype (patients Erl2 and Erl4) 13. The 
remaining 10 MWS-like cases are unpublished, but could be classified in either of these 2 groups. 
All were mentally retarded, and 9 out of 14 had HSCR (Table 2). These 14 MWS-like patients were 
found to be negative for whole gene deletions or intragenic mutations in ZFHX1B.
Table 2. Overview of the ZFHX1B-negative Mowat-Wilson-like syndrome and
polymicrogyria cases analysed in this study
MWS like 
patients
Sex MR Micro
cephaly
Seizures HSCR PMG Other
Erl1 M + + + + congenital heart defect, cerebral 
atrophy, fetal finger pads
Erl2 F + - - + cleft palate
Erl3 M + + ND + polydactyly
Erl4 M + + - +
Erl5 M + + + ND sibs, consanguineous parents, 
agenesis of the corpus callosum, 
optical and cortical atrophyErl6 F + + + ND
Erl7 M + - + + 3 further affected sibs; 1 with 
HSCR
Erl8 M + ND ND + abnormal genitals
Erl9 F + - ND + renal anomaly
Erl10 F + + + - agenesis  of the corpus callosum
SB M + + - + CHD, broad gyri of the frontal 
cortex
SF F + + + - constipation
MS F + + - - agenesis  of the corpus callosum
KAL M + ND - + unilateral cleft lip/palate
PMG1 F + - + - fronto-parietal spasticity, affected brother
PMG2 F + - + - biparietal hypotonia, consanguineous 
parents
PMG3 M + - + - bilateral 
parieto-
occipital
spasticity, consanguineous 
parents
PMG4 M + - - - closed lip 
schizencephaly
spasticity
PMG5 F + - + - bilateral diffuse nystagmus, spasticity, 
kyfoscoliosis
PMG6 M + + - - biparietal strabismus
ND: not documented.
MR: psychomotor retardation; HSCR: Hirschsprung disease; PMG: polymicrogyria; CHD: congenital heart 
defect
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Sporadic HSCR patients and PMG cases
Twenty-six sporadic HSCR patients (23 with short-segment aganglionosis and three with unknown 
length of aganglionosis) and six cases (PMG1-PMG6) with bilateral polymicrogyria and suggestive 
autosomal recessive inheritance (Table 2) were also screened for mutations in KIAA1279.  In the 
latter PMG group microdeletions of 22q11 19 were excluded. 
Molecular analysis of KIAA1279 
Genomic DNA was isolated from peripheral leukocytes by the use of standard methods. Sequencing 
of exons 1-7 of KIAA1279 was performed using 9 sets of primers (Table 3). DNA amplification 
was performed using 25-100ng genomic DNA in 30 μl PCRs containing 10X reaction Buffer, 8 
μM primer pair mix, and 1 U Taq Polymerase (Amersham). PCR products were amplified and 
purified (Multiscreen PCR u96 Filter Plate -Millipore-). Unidirectional sequencing was performed 
using BigDye Terminator chemistry on an ABI 3100-16 capillary sequencer (Applied Biosystems). 
Using the software package SeqMan II (Version 5.07, DNASTAR) DNA sequences were aligned and 
compared with consensus sequences.
Table 3. PCR primers and conditions for amplification of KIAA1279 exons
Primer
Sequences bp Size(bp) Tm °C Exon
seq.
primer
KIAA1AF CAACGTGTCGAGAGCCGTAA 20 424 58 1 1AF
KIAA1AR CTCCGTGTCGATGTGGTTCA 20
KIAA1BF TCCGGAGAAGGAACCATACA 20 446 58 1 1BF
KIAA1BR GAATTGCGCCTTACAACGTC 20
KIAA2F CTGCACTACATAAGGTCAAT 20 355 58 2 2F
KIAA2R AGTGAAGAGTCACACCAATA 20
KIAA3F TTGGCTTGTAGAAGTTGA 18 277 52 3 3F
KIAA3R GAATCCACATTCTATAACC 19
KIAA4F1 GCCTGACTATTATGGTGAA 19 479 58 4 4R1
KIAA4R1 CTCACTATTGGTACTCTGTA 21
KIAA5F TTCTGAATGATCTGCAACTC 20 328 58 5 5F
KIAA5R CTCTTCTGTTCTTGCAACTT 20
KIAA6F ACAGTTGTGACCATTAACTT 20 281 58 6 6R
KIAA6R ACATTCTACACACCTTTCAT 20
KIAA7AF GGAGGTGAGTGTCCTACTTA 20 423 58 7 7AR
KIAA7AR GCTCTAGCATGGCTATTCTG 20
KIAA7BF ACCACAGTGCTCTGTTTAAGG 21 427 58 7 7BF
KIAA7BR TCCAGCTCTTTCTTGGGATCT 21
KIAA7CF AGACCCAAATAAATGTATTCC 20 390 58 7 7CF
KIAA7CR CTGGCTATAAAGGTAAACAT 20
F= forward, R=reverse
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Results
Clinical data
Family 1 
Patients US1 and US2 were previously reported by Goldberg and Shprintzen as the first patients 
with GOSHS 1. These sibs manifested an unusual facies (microcephaly, fine scalp hair, apparent 
hypertelorism, synophrys, thick curly eyelashes, prominent nose, and maxillary hypoplasia), 
neonatal hypotonia, short stature, HSCR, and a submucous cleft palate.
Both siblings are now adults: US1 is 40 and US2 is 37 years old. They both had surgery for 
severe scoliosis. Furthermore, US 2 had corneal transplants because she suffered from recurrent 
corneal infections. Revision of MRI of the brain of US1, performed at the age of 37 years because of 
abnormal gait and lack of balance, showed a simplified gyral pattern and diffuse white matter loss. 
Unfortunately, the quality of the MRI was insufficient to rule out PMG.
 
Family 2 
Family 2 is originally from Cyprus. The family resides in Australia, and the parents, although not 
known to be consanguineous; both originate from the same village in Cyprus. Their first child, a girl 
is healthy. The male proband (CYP1) in this family, is their second child. The pregnancy of the index 
patient was complicated by hyperemesis, and was induced at term resulting in a normal vaginal 
delivery. This infant’s birth weight was 3100 g, OFC 33 cm (< 10th percentile). The finding of delayed 
passage of meconium led to the suspected diagnosis of HSCR. A rectal biopsy done on day 4 was 
consistent with the diagnosis of HSCR. On examination he was hypotonic, with severe progressive 
microcephaly with an OFC of 33.1 cm at 4 months (<< 3rd percentile). He had dysmorphic features 
including: a low anterior hairline, overriding sutures, open mouthed posture, arched and prominent 
eyebrows, long, thick and curled eyelashes, prominent nasal bridge, a pointed chin, and long, slender 
fingers and toes (fig 1). 
Microcephaly and irregularity of the cortical grey/white matter junction were seen on 
cerebral MRI consistent with polymicrogyria, involving the entire hemispheres with sparing of the 
inferior frontal lobes, inferior portion of the Sylvian fissure and the medial lobes. A skeletal survey 
was normal. A mild pelvicalyceal dilatation was reported on ultrasound. Conventional karyotyping, 
subtelomeric FISH, and FISH for the MWS region, were normal. Mutation analysis of the ZFHX1B 
gene by direct sequencing was negative. Given the child’s poor prognosis and his expected severe 
neurodevelopmental delay, a joint medical and parental decision was made for conservative care 
of HSCR. He died at 6 months of age. The family history is of particular relevance. A female 
second cousin (CYP2) of the mother of the proband suffers from chronic constipation, mental 
retardation, scoliosis, and leg muscle weakness. Moreover, a brother of CYP2 died at 2 months of 
age after complicated surgery for HSCR. Further clinical details of this boy are lacking. Review of 
the photographs of CYP2 confirmed that this girl has GOSHS. The medical history of her brother 
is also suggestive for GOSHS.
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Figure 1
CYP1 as a neonate. Note the high-arched eyebrows, and microcephaly.
UK2 at age 5 years. Note the high- arched eyebrows.
UK1 at age 7 years. Note the high-arched eyebrows, and the high nasal bridge.
Family 3 
In the third Caucasian family, 2 sons (UK1 and UK2) of a non-consanguineous couple of British 
ancestry were diagnosed with HSCR. For an extensive clinical description see Murphy et al. 
(submitted). UK1 is now 8 years of age (fig 1). Passing of meconium was delayed and he developed 
a lower bowel obstruction within 48 hours after birth, which was suggestive of HSCR. Colonic 
biopsies were consistent with long-segment HSCR. His OFC at birth was < 3rd percentile. He 
currently is microcephalic (OFC < 3rd percentile), whereas his height and weight are normal (25th-
50th percentile). On examination he was noted to have high-arched eyebrows, down slanting of 
the palpebral fissures, bilateral ptosis, prominent ears, sloping forehead, a prominent nose, and a 
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short philtrum. At age of 12 months, his psychomotor development was delayed and equivalent to 
a chronological age of 6 months. His motor milestones were delayed: he sat at 13 months, walked 
independently at 4 years, and began to talk at 2 years and 10 months of age.  At age of 71/2 years, 
his development is moderately retarded. Brain MRI at the age of 2 years, performed after he had an 
absence seizure, was reported as normal. UK2, a 6-year-old boy (fig 1), is the second child of this 
British couple. He was born after an uneventful pregnancy. His birth weight was 3120 g (10th-25th 
percentile); OFC was 31 cm (< 3rd percentile). Failure to feed and vomiting were indications for 
transfer to the pediatric surgical unit.  Short segment HSCR was diagnosed; he had a temporary 
colostomy at 2 days of age, and intestinal reconstruction at the age of 2 months. He was noted 
to have an ASD and a submucous cleft palate. At age 7 months, he manifested a flat occiput and 
a remarkable physical resemblance to his elder brother; he has high-arched eyebrows, curled 
eyelashes, large anteverted ears and a prominent nose. His psychomotor development is markedly 
delayed; he sat at 12 months, and walked at 22 months of age. At 51/2 years of age, he is only 
able to follow simple verbal instructions. Brain MRI at age 7 months, showed asymmetrical lateral 
ventricles, but was not conclusive for a malformation of cortical development. Neither corneal 
hypoesthesia nor recurrent corneal infections were reported. Both boys have a normal 46, XY, 
male karyotype. FISH analysis of the ZFHX1B region showed no submicroscopic deletions. 
Family 4 
Previously we identified a homozygous mutation in the KIAA1279 gene 7, in the family described 
by Hurst and others 2. Clinical follow-up of this British-Pakistani family revealed that 2 additional 
affected children were born in this family. A sister (BP1) of case 1 has typical facial characteristics 
(ptosis, a prominent nasal bridge, a high arched palate), microcephaly (OFC< 3rd centile) and was 
diagnosed with HSCR. A sister of case 2 (BP2) has the typical GOSHS Gestalt (prominent nasal 
bridge, high arched eyebrows), is microcepalic and also exhibits developmental delay, but she did 
not have HSCR.  Case 1 was noted to have a clumsy, slightly broad base gait and he appeared 
slightly ataxic. He died at the age of 20 years because he had respiratory failure as a consequence 
of a progressive scoliosis. 
Molecular analysis of KIAA1279
Table 4 summarizes the KIAA1279 mutations found in this and in our previous study.
In family 1, a homozygous insertion of an A at nucleotide 1551 in exon 7 of KIAA1279 leading to 
a frameshift and a premature stop codon was found in US1 and US2. The parents were both 
heterozygous carriers of this mutation.
In family 2, a G→T substitution at nt 753 in exon 4 was identified that results at the protein level in 
the replacement of a glutamic acid with a stop codon (E240X). This nonsense mutation was found 
homozygous in CYP1, whereas the parents of CYP1 were both heterozygotes.
In family 3, the boys (UK1 and UK2) and their father are heterozygote for an insertion of an A at nt 
1117, leading to a frame shift with a premature stop. We have not identified a second mutation so 
far but analysis is on-going.
In family 4, the  British-Pakistani family described by Hurst et al. 2, we previously identified a 
homozygous G→T transversion at nt 285, resulting, at the amino acid level , in the replacement of 
a glutamic acid with a stop codon (E84X).
In family 5 (the Moroccan family) a homozygous nucleotide substitution 303C→T, leading to the 
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replacement of an arginine with a stop codon at the amino acid level (R90X) was identified 7. All 
mutations identified so far are inactivating
No KIAA1279 mutations were identified in 26 HSCR cases, in 6 cases with PMG and in the 
group of possible MWS-like cases.
Discussion
Clinical spectrum
GOSHS is a clearly defined clinical entity, and although rare, it can be recognized in children from 
different geographic regions and ethnic backgrounds. Moderate mental retardation and microcephaly 
(which can be progressive as in case CYP1 of family 2 and patient V.6 in family 5 (Moroccan family 
6) are obligate (Table 1). The facial Gestalt is discrete and consists of high arched eyebrows, curled 
eyelashes, and a prominent nose. HSCR of variable length occurred in all 5 families, but not every 
GOSHS case had HSCR: CYP2 in family 2 suffered from constipation, but was never diagnosed 
as having intestinal aganglionosis. In total 13/16 (81%) affected cases in these 5 families had HSCR 
(Table 4). Therefore, HSCR is a variable and not a mandatory feature in GOSHS. This is consistent 
with earlier observations 5. Possibly, like in MWS, also in GOSHS the actual frequency of HSCR 
is lower than presented here, as a selection bias in recognizing families with HSCR might have 
occurred 13. 
Diffuse PMG could be part of the core phenotype, but this feature is likely to be 
underdiagnosed because of the lack of detailed MRI studies in many cases. So far in 4/5 families with 
mutations in KIAA1279, brain MRI studies were performed. In 2 families (family 2 and family 5) PMG 
was diagnosed 7 , whereas in the other 2 families (family 1 and family 3) PMG was clinically suspected, 
however revision of the available MRIs was inconclusive. Importantly, the MRI studies of the eldest 
GOSHS patient, US1 of family 1, showed a simplified gyral pattern and a diffuse white matter loss. 
Although a simplified gyral pattern is actually classified as a defect of cortical proliferation, distinct 
from PMG (often classified as a postmigratory defect) 20 , its presence suggests that malformations 
of cortical development represent core features of GOSHS, and underlie the obligate microcephaly. 
Table 4. KIAA1279 mutations in GOSHS patients from this study and the literature
Mutation Type Exon Family Reference
c.1551-1552insA Frameshift  7
Family 1(US) with 2 
affected sibs
This study
c.753G>T Nonsense  4
Family 2 (CYP) with 3 
affected probands
This study
c.1117-1118insA Frameshift  7
Family 3 (UK) with 2 
affected sibs
This study
c.285G>T Nonsense  1
Family 4 (British-
Pakistani family) with 
4 affected patients
2, 7
c.303C>T Nonsense  1
Family 5 (Moroccan 
family) with 5 affected 
patients
6, 7
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We, therefore, recommend that every child with HSCR and mental retardation and/or microcephaly 
is referred to a pediatric neurologist and that a MRI of the brain is performed. Furthermore, MRI 
studies in adolescent and adult GOSHS cases are needed to study whether progressive white matter 
loss is part of the GOSHS phenotype. 
Additional features present in some but not all of the patients include corneal infections 
requiring corneal transplants (present in 2 cases from family 5 -the Moroccan family- and in US2 from 
family 1 at an older age), and progressive scoliosis (present in all children who reach adolescence). 
This progressive scoliosis was associated with pulmonary failure and early death in 2 cases (case 
V.6 of family 5 died at 15 years, and case 1 of family 4 -the British-Pakistani family- died at age 20 
years, respectively) 2, 6. We underlined earlier that neurological and ophthalmologic complications 
may develop at an elder age in GOSHS. Follow-up of the original 2 cases reported by Goldberg 
and Shprintzen and the cases described by Hurst confirmed this observation 1, 2, 6. These 2 features 
warrant clinical follow-up by a neurologist and an ophthalmologist. Well-timed surgery to correct 
the scoliosis might improve the prognosis. 
Mutational spectrum 
We have identified 12 patients from a total of 5 unrelated pedigrees with KIAA1279 mutations to 
date. The pattern of transmission observed is consistent with an autosomal recessive trait, with 
occurrence in both sexes and consanguinity in 2/5 families (families 4 and 5, and possibly in family 
2 originating from Cyprus). We identified in total 5 different mutations in the KIAA1279 gene, 4 of 
which were homozygous. These include 3 nonsense (family 2, 4 and 5), and 2 frame shift mutations 
(family 1 and 3). In family 3 (the UK family) we did not identify a second mutation; one possible 
reason is that a large deletion (>100 bp) could have been overlooked using a mutational scanning 
method with PCR as a first step. Comprehensive mutation analysis should not only include screening 
of the coding sequences, intron-exon boundaries, and promoter sequences, but also scanning for 
large deletions. Therefore, quantitative PCR studies will be performed in family 3.    
All mutations are inactivating indicating that loss of function of KIAA1279 leads to GOSHS. Non-
syndromic HSCR and PMG unrelated to GOSHS are not caused by mutations in this gene. 
Finally, since not all HSCR cases associated with microcephaly and mental retardation 
can be attributed to mutations in either KIAA1279 or ZFHX1B, there must exist further genetic 
heterogeneity 11.
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CHAPTER 5
TWO SIBS WITH HIRSCHSPRUNG DISEASE AND OVERLAPPING 
PHENOTYPES OF MCKUSICK-KAUFMAN SYNDROME AND 
BARDET-BIEDL SYNDROME
Two sibs with Hirschsprung disease and overlapping phenotypes of McKusick-Kaufman 
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Abstract
We describe a patient with hydrometrocolpos, postaxial polydactyly of the feet, subvalvular 
pulmonary artery stenosis, dysplastic kidneys, and short-segment Hirschsprung disease (HSCR), 
in which the presumptive diagnosis of McKusick-Kaufman syndrome was made. Her brother was 
diagnosed with Bardet-Biedl syndrome based on the combination of four limb postaxial polydactyly, 
hypogenitalism, cystic dysplastic kidney changes and long-segment HSCR. 
Sequencing 3 of the 9 BBS genes (BBS1, BBS2, and MKKS/BBS6) did not reveal any mutations. 
Mutation scanning of RET, the major gene in HSCR, revealed a sequence variant Lys716Asn in exon 
12 in the affected girl, but not in the affected brother. It is uncertain whether this variant contributes 
to HSCR in this family. The existence of a gene causing the combination of BBS/MKKS and HSCR 
can however not be excluded.   
Introduction
McKusick-Kaufman syndrome (MKKS, OMIM 236700) and Bardet-Biedl syndrome (BBS, OMIM 
209900) are rare autosomal recessive syndromes with overlapping clinical and molecular spectrum. 
Hydrometrocolpos is regarded as a primary sign in MKKS. Other hallmarks of MKKS are kidney 
abnormalities (hydronephrosis secondary to hydrometrocolpos, primary cystic kidney disease) 
postaxial polydactyly and congenital heart disease (predominantly septal defects) 1. 
BBS is characterised by rod-cone dystrophy, postaxial polydactyly, central obesity, mental 
retardation, hypogonadism, and renal dysfunction 2. 
Since hydrometrocolpos may occur as a neonatal manifestation of BBS syndrome 3 4, while 
the main clinical features such as retinitis pigmentosa and obesity may not be apparent in infancy and 
early childhood 5, no definite distinction between BBS and MKKS can be made on clinical grounds 
in a young child. Phenotypic features that allow discrimination between the two syndromes in the 
neonatal period do not exist, although it was suggested that upper female genital tract malformations 
(uterine, ovarian, and fallopian tube abnormalities) are rare in MKKS, but common in BBS 6. Clinical 
follow-up of these patients include ophthalmologic studies, monitoring of weight and development, 
and will eventually permit discrimination between MKKS and BBS 7, 8. As MKKS was shown to be 
caused by one of the BBS genes (BBS6/MKKS) the distinction between both syndromes is no longer 
clear 9, 10 11.
Hirschsprung disease (HSCR), a congenital disorder of the enteric nervous system, 
characterized by the absence of ganglion cells from the bowel wall 12, can be a feature of both 
MKKS and BBS. HSCR is a also a variable feature in a large number of uncommon autosomal 
recessive inherited syndromes, such as Shah-Waardenburg syndrome, Smith-Lemli-Opitz 
syndrome, Goldberg-Shprintzen syndrome 13, Mowat-Wilson syndrome and Congenital Central 
Hypoventilation syndrome 14.  
The elucidation of the genetic background of both MKKS and BBS, as well as HSCR has 
been fruitful with the identification of 9 BBS genes 15 16 and 10 genes and 4 loci for HSCR 17. Functional 
studies show emerging evidence that some of the BBS proteins are involved in multiprotein complexes 
that localize to centrosomes 15.  Centrosomal dysfunction is not only associated with abnormalities 
in cell division and chromosomal segregation, but can also lead to abnormal neuronal migration and 
assembly of cilia 18. The main purpose of the RET signalling pathway, the major pathway involved in 
HSCR development, is the migration of the enteric nervous system precursors into the foregut 19.   
The aim of this paper is to present a clinical description and molecular studies in a family 
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with 2 sibs affected with the combination of HSCR and a syndrome representing McKusick-Kaufman 
syndrome or Bardet-Biedl syndrome. 
Patients
Case 1
The proband, a girl, is the first child of parents of native Dutch origin. Their family history was 
unremarkable and in particular there was no prior history of bowel dysfunction in either parent. 
Consanguinity between the parents or grandparents was unknown, however four of the eight 
grandparents originated from a small Dutch island in the south of the Netherlands. 
At prenatal fetal ultrasonography in the third trimester mild hydrops fetalis, mild 
ventriculomegaly of the brain, cystic kidneys and a large abdominal cyst were noted. Polydactyly of 
the feet was suspected. Amniocentesis at 32.5 weeks was performed and showed a 46, XX normal 
female karyotype and an elevated alpha-fetoprotein level (28.5 mg/L) (normal < 5mg/l). Birth was 
preterm at 33 4/7 weeks. Birth weight was 3,155 g (>p97). Her abdomen was extremely distended 
and a mass was palpable. She had generalized edema (fig 1a). Abdominal ultrasonography showed 
that the abdominal mass was due to hydrometrocolpos, which was surgically treated at day 2. X-
rays showed fusion of metacarpals III and IV of the left hand, and postaxial polydactyly of both feet 
(fig 1b). Cardiological evaluation revealed an asymptomatic subvalvular pulmonary artery stenosis. 
Ophthalmologic studies were normal in the neonatal period, however she gradually developed mild 
myopia (-3/-3) during childhood. Since intestinal obstruction persisted after surgical correction 
of the hydrometrocolpos, HSCR was suspected. Suction biopsy showed an aganglionosis of the 
recto-sigmoid colon (short-segment HSCR). A low anterior resection (Rehbein) with a primary 
anastomosis was performed at 14 months. Dysmorphologic evaluation at 2 months also showed 
frontal bossing and deep-set eyes. She had dysplastic, malfunctioning kidneys with a glomerular 
filtration rate 35ml/min/1.73m2 at the age of 7 (normal value 100ml/min/1.73m2). 
Figure 1 
Female patient
a. Facial edema in the neonatal period in case 1.
b. X-ray feet showing postaxial polydactyly in case1.
A B
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Case 2
In the second pregnancy prenatal ultrasound studies were performed. A bichorionic-biamniotic 
twin-pregnancy was diagnosed. One male fetus had mild ventriculomegaly of the brain, large kidneys 
and polydactyly of the feet. The other male child had no congenital malformations. Delivery was at 
37 4/7 weeks. The weight of the first-born twin was 2975 g; the second child’s weight was 3420 g. 
The latter twin brother had four limb postaxial polydactyly, with partial digital syndactyly IV-V of 
the left hand. X-rays of the feet showed 6 metatarsal bones, and postaxial hexadactyly (fig 2). He 
was admitted to the pediatric surgical ward because of delayed passing of meconium in addition 
to feeding problems. At day 2, HSCR was suspected; biopsies were taken at laparotomy, showing 
a total colonic aganglionosis, consistent with long-segment HSCR. A perforation of the ileum was 
observed. After ileocecal resection, a temporary ileostomy was fashioned. A final re-anastomosis 
was completed at the age of 5 months. Ultrasound studies of the kidneys showed large dysplastic 
kidneys with some cysts. The glomerular filtration rate was 45ml/min/1.73m2 (normal 100ml/min/
1.73m2). He had a micropenis and a mild phimosis. Ophthalmological studies at the age of 4 years 
showed mild myopia.
Methods
Molecular studies of  BBS1, BBS2, BBS6 and RET.
DNA was isolated from leukocytes prepared according to standard methods. 
BBS1 and BBS2 of the patients were analyzed using capillary heteroduplex analysis.  
The coding exons of MKKS/BBS6 of the patients and parents were sequenced.
DGGE analysis of all exons of RET was performed on the patients and their parents as described 
before 20. 
Figure 2 
Male patient
Postaxial polydactyly of hands and feet in case 2 
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Results
Both BBS1 and BBS2 were analyzed using capillary heteroduplex analysis and proved to be normal. 
Sequencing the coding exons of MKKS/BBS6, revealed two single-base substitutions 
believed to be polymorphisms (Arg517Cys and Gly532Val). 
A mobility shift of exon 12 of RET was detected in both the index-patient and her father. 
Sequencing demonstrated a G to A transition resulting in the amino acid change Lys716Asn. This 
missense mutation was not identified in 70 healthy Dutch controls and in 200 (unselected) HSCR 
patients. This variant was, however, absent in the affected brother with long-segment HSCR.
Discussion 
Clinical findings
At prenatal ultrasound Meckel syndrome (OMIM 249000) was considered in the first-born child 
of this family, based on the combination of postaxial polydactyly and cystic kidneys. Although an 
elevated alpha-fetoprotein level (28.5 mg/L) was found, no encephalocele, neural tube defects or 
abdominal wall defects were present. Recently it was shown that antenatal presentation of BBS 
might mimic Meckel syndrome. In 6/13 cases of prenatally diagnosed Meckel-like cases presenting 
with cystic kidneys and polydactyly without an encephalocele, mutations in 3 Bardet-Biedl syndrome 
genes (BBS2, BBS4 and BBS6) were identified underlining the clinical overlap between these 2 
syndromes 21. 
After birth the presumptive diagnosis of the first-born changed into MKKS based on 
postaxial polydactyly of the feet, hydrometrocolpos and congenital heart defect. The phenotype of 
the affected brother with four limb polydactyly, hypogenitalism, enlarged cystic kidneys with renal 
dysfunction, and myopia, most likely fits BBS (the first 3 being major features) rather than MKKS 
5. This makes the older sister the one who is difficult to classify and illustrates that overlapping 
phenotypes of MKKS and BBS can be present within the same family, which is consistent with the 
idea that MKKS might represent a hypomorphic variant of BBS 6 , and that MKKS and BBS can be 
caused by mutations in the same gene 10, 11. Although there is significant overlap in clinical features 
between MKKS and BBS, MKKS patients are not obese and do not develop retinopathy. So far both 
sibs have normal weight gains and regular ophthalmology consultations revealed mild myopia but 
no retinopathy. 
The occurrence of HSCR in MKKS and BBS is well documented 22; the simplest explanation 
for this combination is that they co-occur by chance. This seems highly unlikely since the frequency 
of HSCR in MKKS (12-14% or 1:7) 23 6 and in BBS (2-12%) 5, 6 is much higher than the prevalence of 
HSCR in the general population (1:5000) 24. Based on a literature review, Slavotinek and Biesecker 
concluded that a subtype of BBS might exist in which hydrometrocolpos, structural abnormalities 
of the female genital tract, cardiac malformations, gastrointestinal malformations (imperforate anus 
and HSCR), and metacarpal involvement are more common 6.  Also male cases with HSCR and BBS 
are reported 25. 
As far as we know no specific BBS gene has been implicated in the combination of HSCR 
and BBS. We analysed 3 (BBS6, BBS1, BBS2) of the 9 known BBS genes. We selected these genes 
because BBS1 and BBS2 are the genes most frequently mutated in Caucasians 26, and because of the 
fact that BBS6 mutations can either be associated with MKKS or BBS 10, 11. No mutations in these 
BBS genes were found. Given the occurrence of HSCR in both patients, we decided to screen RET, 
the major gene involved in HSCR susceptibility. A RET missense mutation Lys716Asn was identified 
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in the index patient and her father, but was not present in the second affected patient. Therefore, 
the Lys716Asn mutation cannot be the sole determinant of the extended phenotype in this family. 
Whether it contributes to the HSCR phenotype is hard to say as functional data of this variant are 
lacking. In favour of a causative role are the observations that i) this substitution involves amino acids 
that differ in polarity and size, ii) the Lys716Asn substitution was not identified in 70 healthy Dutch 
control individuals, and iii) Lysine716 is located just outside the tyrosine kinase domain, a region which 
is highly conserved between different species. Given the prior evidence for oligogenic inheritance 
of S-HSCR, involving loci at 3p21 and 19q12 as RET-dependent modifiers 27, we hypothesise that 
the RET gene/protein might interact with one or more BBS genes/proteins, to explain the frequent 
occurrence of HSCR in both syndromes. However, the existence of a gene causing the combination 
of BBS/MKKS and HSCR can not be excluded. 
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CHAPTER 6
A NOVEL SUSCEPTIBILITY LOCUS FOR HIRSCHSPRUNG DISEASE 
MAPS TO 4Q31.3-Q32.3
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Abstract
We report on a multigenerational family with isolated Hirschsprung disease (HSCR). Five patients 
were affected by either short-segment or long-segment HSCR. The family consists of two main 
branches, one with 4 patients (3 sibs and 1 maternal uncle) and one with 1 patient, respectively. 
Analysis of the RET gene, the major gene involved in HSCR susceptibility, revealed neither linkage 
nor mutations. A genome-wide linkage analysis was performed, revealing suggestive linkage to a 
region on 4q31-q32 with a maximum parametric multipoint LOD score of 2.7. Furthermore, non-
parametric analysis of the genome-wide scan data revealed a NPL score of 2.54 (p= 0.003) for the 
same region on chromosome 4q (D4S413-D4S3351). The minimum linkage interval spans a region 
of 11.7 cM (12.2 Mb). No genes within this chromosomal interval have previously been implicated in 
HSCR. Considering the low penetrant-disease in this family, the 4q locus may be necessary but not 
sufficient to cause HSCR in the absence of modifying loci elsewhere in the genome. Our results are 
suggesting the existence of a new susceptibility locus for HSCR at 4q31.3-q32.3.
Introduction 
Hirschsprung disease (HSCR, OMIM 143623) is a congenital disorder characterized by the absence 
of enteric neurons, which are neural-crest derived, in the digestive tract. Delayed passage of 
meconium is the cardinal symptom in neonates with HSCR. If untreated, bowel hypomotility 
leads to severe constipation often associated with obstruction, gross distention of the bowel and 
vomiting. The prevalence of HSCR is approximately 1 in every 5000 liveborns. In the majority of 
cases (75-80%) the aganglionosis typically involves the rectum and the sigmoid (short segment 
Hirschsprung disease: S-HSCR). In 20-25% of the patients the aganglionosis extends proximally of 
the rectosigmoid, and the disease is called long segment HSCR (L-HSCR) 1. HSCR mostly presents 
as an isolated congenital malformation (non-syndromic HSCR), but can be found in association with 
other congenital abnormalities (syndromic HSCR) 2.
So far mutations in 10 genes (RET, GDNF, EDNRB, EDN3, ECE1, SOX10, ZFHX1B, NTN, 
PHOX2B, and KIAA1279) have been implicated in HSCR 3 4 5 6 7, 8 9 10 11 12, 13 14 15 16.
The RET gene located at 10q11.2 is the major susceptibility locus in HSCR: 15-35% of 
the sporadic patients have inactivating mutations in the coding sequence of RET 17 18 19 20, whereas 
linkage analysis showed that all, but one, autosomal dominant families are linked to RET 21. High-
penetrance mutations in the coding sequence of the RET gene, however, are found in only 50% of 
the RET-linked families. RET-linked multigenerational families without a coding sequence mutation, 
might have a mutation in the non-coding sequence of the RET gene, including alterations in intronic 
and promoter sequences or harbor (frequent) variants that do change the function of the RET 
protein slightly 21. Furthermore, similar haplotypes are found in the 5’ region of the RET locus in 
HSCR populations patients from all over the world indicating the segregation of identical ancestral 
variant(s) 22 23 24 25 26. Evidence is accumulating that specific (common) non-coding low-penetrance 
variants just before the gene and within intron 1 of RET are associated with HSCR susceptibility 22 
25 27 28 29 30.
Single mutations leading to either isolated or syndromic HSCR have been found in the 
above-mentioned 10 genes, although evidence is building up that HSCR is a multigenic congenital 
malformation in the majority of HSCR patients. A “multiplicative model” has been suggested which 
assumes that additional loci are involved apart from the RET locus, and their individual effects can 
be multiplied.31 
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Furthermore, 4 HSCR susceptibility loci (9q31, 3p21, 19q12, and 16q23) have been identified, 
harboring unidentified genes 21 31 32.  Linkage at 9q31 was reported in 5 families that also showed 
linkage with RET, however no causative RET mutation could be identified. A sixth family that was 
RET-unlinked, however, was linked to the locus at 9q31 21. Furthermore susceptibility loci at 3p21 
and 19q12 have been identified in affected nuclear families, suggesting that these 2 loci probably 
function as RET- dependent modifiers. Non-random allele sharing was also found at 9q31 in those 
nuclear families in which no RET mutation was identified, confirming the segregation of the 9q31 
locus in multiplex families 31 21. 
In an inbred Mennonite population, RET not only interacts with EDNRB, but also with an 
unknown gene on chromosome 16q23. This locus is probably only of importance in this genetic 
isolated population 32 in which HSCR can be associated with symptoms also found in Waardenburg-
Shah syndrome 7. Conversely, no linkage with the other susceptibility loci at 3p21, 9q31 and 19q12 
was found in this Mennonite kindred.
Clearly, HSCR is a heterogeneous congenital malformation. It is estimated that only 30% 
of cases can be attributed to mutations of the known genes 33.  Thus, a considerable number of 
additional genes involved in enteric nervous system development might be identified in the future 
28. Here, we describe a five-generation family with non-syndromic HSCR with suggestive evidence 
for a new susceptibility locus on chromosome 4. 
Methods
Patients
The family we describe here is a five-generation pedigree of native Dutch origin with 5 cases 
presenting HSCR. The segregation pattern is compatible with an autosomal dominant mode of 
inheritance with incomplete penetrance. One branch of the family consists of a sibship with 3 affected 
children and an affected uncle. Two sisters (V-1 and V-3) have S-HSCR. Their brother (V-2) was 
diagnosed with total intestinal aganglionosis, both large and small intestines were aganglionic. Given 
the boy’s poor prognosis, a joint medical and parental decision was made for conservative care of 
HSCR; he died at the age of 1 month. Delayed passage of meconium led to the suspected diagnosis 
of HSCR in all 3 children. Suction and/or full thickness biopsies were consistent with this diagnosis. 
Their maternal uncle (IV-3) was operated during childhood because of S-HSCR. The other branch 
of the family contains one affected female with S-HSCR (V-4). Her paternal grandfather (III-3) is a 
cousin of the maternal grandmother (III-2) of the 3 sibs (fig 1). Congenital malformations indicative 
of syndromic HSCR were lacking in all 5 patients as confirmed by two dysmorphologists (ASB and 
IVL). Karyotyping was normal in patients V-1 and V-2. Brainstem evoked response audiometry, 
which we performed because of his expected early death and to exclude hearing loss consistent with 
Shah-Waardenburg syndrome, showed no abnormalities in patient V-2. Chronic severe constipation 
was not reported in II-2, III-2, IV-4, although IV-2 as well as her father III-1 suffered from severe 
constipation in childhood. Informed consent was given by the parents and the adult patient (IV-3). 
Genomic DNA was isolated from peripheral blood obtained from II-2, III-2, IV-1, IV-2, IV-3, IV-4, 
IV-5, V-1, V-2, V-3 and V-4 using standard protocols 34.   
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Figure 1
Pedigree structure and haplotypes. Patients are represented as blackened symbols. The segregating 4q31-q32 haplotype is depicted. 
The minimum critical region at chromosome 4 spans 11.7 cM between D4S3049 and D4S1566.
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Analysis of markers encompassing the RET locus
The following markers: D10S141 (- 1 Mb to RET), RETint5, D10S1099 (1.4 Mb downstream to RET) 
and 5 SNPs (rs741763, rs2435362, rs2565206, rs2506004) from the 5’RET region were analyzed as 
reported by us elsewhere 26 27and rs2435357 reported by others 28.    
Mutational analysis of RET 
Mutation analysis of the 21 exons of RET was performed in probands V-1 and V-4, as described by 
us elsewhere 20. 
Genome wide linkage analysis
We performed a systematic genome scan using the ABI Prism MD-10 set (Applied Biosystems) 
consisting of 382 markers (STRPs), with an average spacing of 10 cM. Additional markers for further 
characterization of candidate regions were selected from the sex-average Marshfield genetic map 
or newly designed. Genomic DNA (20 ng) was used as a template in 7.5 μl PCR reactions, with 5 
pmol of oligonucleotides, 0.3 units Amplitaq Gold polymerase in Gold buffer (Applied Biosystems) 
and 2.5 mM MgCl2. The thermal cycling consisted of an initial incubation at 95 oC for 5 minutes, 
followed by 10 cycles of 95 oC for 30 seconds, 55 oC for 15 seconds and 72 oC for 30 seconds 
and 25 cycles of 92 oC  for 30 seconds, 55 oC for 15 seconds and 72 oC for 30 seconds. PCR 
products were pooled and loaded on an ABI3100 automated sequencer (Applied Biosystems). Data 
were analyzed using GeneMapper software (v 2.0). Mega2 35 was used to process the genetic data 
into the appropriate format and perform data validation checks. Simulation analysis to estimate 
the probability of detecting genetic linkage given the pedigree structure (statistical power) was 
performed with the SLINK program 36. Due to uncertainties related to the correct genetic model 
in this pedigree, parametric and non-parametric linkage analyses were performed using SimWalk2 
(version 2.9) 37.
For the parametric analysis we specified an autosomal dominant mode of inheritance, a mutant 
allele frequency of 0.01% with a penetrance of 40% and equal marker allele frequencies. Pedigree’s 
Location Scores were calculated; these location scores are directly comparable to multipoint LOD 
scores. For the non-parametric analysis, the max-tree statistic (the largest number of affecteds 
inheriting an allele from one founder-allele) is reported. This statistic was designed for traits best 
modeled by dominant inheritance and was formerly known as STAT B. The NPL_ALL (STAT E) 
statistics, a measure of whether a few founder-alleles are overly presented in affecteds (suitable for 
an additive model) is reported as well. A large value of the statistic indicates a high degree of identity 
by descent (IBD) allele sharing among the patients, usually a result above 2 can be considered 
significant. Empirical p-values (10,000 simulations) are also reported. Namely, this p-value is the 
probability of obtaining a value for that statistic equal to, or more extreme than, the observed value, 
if the trait were unlinked to the markers.
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Results
Linkage analysis to the RET locus and sequence analysis of the RET gene
The family we investigated is a five-generation pedigree of native Dutch origin with 5 cases presenting 
HSCR (fig 1). Since the majority of the multigenerational families with HSCR show linkage to the RET 
gene 21, we investigated the RET locus by haplotype analysis and mutational analysis. We observed 
that not all 5 patients (IV-3, V-1, V-2, V-3 and V-4) shared the same haplotype at the RET locus (Table 
1), excluding linkage with the RET locus in both branches of this family. However, IV-2, IV-3, V-1, 
V-2, and V-3 from branch 1 did share the same haplotype encompassing the RET locus, which must 
be inherited from III-1. We also performed sequence analysis of the entire coding region of the RET 
gene. Direct sequencing revealed no mutations in patients V-1 (branch 1) and V-4 (branch 2). 
Genome search
Simulation analysis (SLINK) yielded an average LOD score of 1.54 and a maximum of 2.15. We 
performed a genome wide search using 382 STRPs. Results from the parametric linkage analysis 
excluded most of the genome (data not shown). Only two genomic regions displayed LOD 
scores above 1, a region on chromosome 17 (D17S798 mLOD score=1.15) and on chromosome 
4 (mLOD=1.84). We tested additional markers and performed haplotype analysis. The region 
on chromosome 17 was rapidly excluded since one patient (IV-3) was not sharing the haplotype 
observed in patients from branch 1.  
The highest multipoint LOD score (mLOD=1.84) was obtained for chromosome 4 
between markers D4S424 and D4S413. This region fully segregated with the disease phenotype (fig 
1). When we saturated the chromosome 4 region with additional markers, a maximum mLOD of 
2.7 (fig 2) was reached between markers D4S1585 and D4S3351 which is consistent with suggestive 
linkage according to the Lander-Kruglyak guidelines for significance thresholds 38.
We also performed non-parametric analysis for our genome wide scan data. Only for this 
region on chromosome 4q, we found non-parametric scores (NPL) above 1. The maximum NPL 
was found for marker D4S413 (158.0 Mb, NCBI build 35.1) located between markers D4S1585 and 
D4S3351 (NPL=2.55, p=0.003), under both dominant and additive mode of inheritance (table 2).  
Table 1. RET haplotypes. Affected family members are in bold.
Family members
II-2 III-2 IV-1 IV-2 IV-3 IV-4 IV-5 V-1 V-2 V-3 V-4
D10S141 3   1 3  2 2  2 4  3 4  2 3  4 2  2 2  4 2  4 2  4 3  2
rs741763 C  G C  G G  G C  C C  G C  C G  G G  C G  C G  C C  G
rs2435362 C  C C  C A  A C  C C  C C  C C  A A  C A  C A  C C  C
rs2435357 C  C C  C T  T C  C C  C C  C C  T T  C T  C T  C C  C
rs2506004 C  C C  C A  A C  C C  C C  C C  A A  C A  C A  C C  C
rs2565206 G  T G  T G  G G  G G  T G  G T  G G  G G  G G  G G  T
Retint5 3   2 3  2 1  3 2  3 2  2 3  1 2  1 1  2 1  2 3   2 3  2
D10S1099 5   2 5  5 5  4 5  5 5  5 2  3 5  1 5  5 5  5 4   5 2  5
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Recombination events can be identified in individual IV-4 (and V-4) and show that marker D4S2962 
at the centromeric site, and D4S2368 at the telomeric site limits the critical region. The maximum 
critical region between D4S2962 and D4S2368 spans approximately 16.4 cM (19.7 Mb according 
to NCBI physical map, build 35.1), the minimum shared region extend from marker D4S3049 until 
D4S1566 (11.7 cM or 12.2 Mb).
Table 2. Results from the non-parametric analysis on chromosome 4q after fine mapping
Marker
Name
Genetic Position
cM*
Physical Position
Mb†
Max-tree‡ NPL_All§ Empirical
p-value
D4S1575 132.1 135.1 0.35 0.38 0.418
D4S1644 143.3 142.1 0.80 0.83 0.148
D4S424 144.6 142.6 0.82 0.84 0.143
D4S1625 146.0 143.9 0.84 0.85 0.141
D4S1586 147.1 147.1 0.87 0.86 0.136
EDNRA -- 148.8 0.86 0.86 0.137
D4S2962 153.0 150.7 0.87 0.86 0.137
D4S3049 155.2 155.1 1.60 1.60 0.025
D4S1585 158.0 157.9 2.42 2.42 0.004
D4S413 158.0 158.7 2.54 2.55 0.003
D4S3351 158.7 159.9 2.54 2.54 0.003
D4S2997 158.7 160.0 2.52 2.51 0.003
AAC1A2 158.0 160.0 2.51 2.51 0.003
D4S3046 162.5 163.7 1.55 1.57 0.030
D4S1566 166.9 167.3 0.99 0.99 0.102
D4S2368 167.6 169.1 0.83 0.84 0.144
D4S1597 169.4 170.2 0.74 0.79 0.163
D4S2431 176.2 175.2 0.51 0.63 0.234
D4S415 181.4 179.1 0.10 0.11 0.776
* According to Marshfield sex average genetic map
† According to NCBI physical map, build 35.1
‡Max-tree is the allele-sharing statistic for traits best modeled as dominant inheritance.
§NPL-All is the statistics for traits following an additive inheritance. 
Figure 2 
Multipoint LOD-score analysis with 
several markers on chromosome 
4. The X- axis represents the 
chromosomal position of the 
markers. The Y- axis indicates the 
multipoint LOD score, with a peak 
LOD score of 2.7. 
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5’ RET common risk haplotype analysis
To test whether non-coding low-penetrance variants just before or within intron 1 of RET were 
associated with HSCR susceptibility in a part of this family, we typed 5 SNPs all being part of an 
ancestral haplotype 27. Spouse IV-1 (married-in individual) was homozygote for the GATAG haplotype 
that is part of the core risk SNP haplotype detected in European, Asian and  European-American 
patients with sporadic HSCR 27 28, 39. The 3 affected sibs (V-1, V-2 and V-3) were thus carriers of the 
core risk haplotype. However, the other 2 patients (IV-3 in branch 1 and V-4 in branch 2) were not 
carrying the 5’ RET common risk haplotype (Table 1). 
Discussion
We identified a five-generation family with 5 patients affected with HSCR. The patients were 
connected to a common ancestor within 3-4 generations. Two branches with HSCR patients within 
the family were identified. The inheritance pattern in the family is compatible with an autosomal 
dominant mode of inheritance with reduced penetrance of a single mutated gene. 
Since RET is the major gene involved in HSCR susceptibility in multigenerational families 21, 
linkage to the RET locus and mutations in the coding sequence of RET were first excluded in both 
branches. However, under the assumption that HSCR is caused by two separate mutations in the 
two branches, an alternative hypothesis would be that the individuals of the main branch with 4 
affected individuals carry a hitherto unidentified RET mutation (introduced in the family by III-1). 
Since an oligogenic model with the contribution of 2 or more loci could not be discarded, as was 
previously demonstrated for HSCR 21, we hypothesized  that the possibility of linkage to RET in 
branch 1, did not mutually exclude the existence of an additional locus in this family.  Subsequently, 
we performed a genome-wide scan to map additional disease gene(s) in this family. Model-free or 
non-parametric linkage analysis methods are more robust than parametric or model-dependent 
analysis, when the mode of inheritance or the genetic model is uncertain, such as the pedigree with 
isolated HSCR reported here. Consequently, we performed both parametric and non-parametric 
linkage analysis. Both methods highlighted the same region on chromosome 4q. No other known 
HSCR susceptibility loci such as the ones at chromosomes 3, 9, and 19 21 31 showed positive LOD 
scores.  When adjacent markers for chromosome 4 were tested, the evidence of linkage became 
stronger and we could observe a common haplotype extending at least 11.7 cM that was inherited 
by all the affected individuals from their common ancestor. Our results are suggesting the existence 
of a novel HSCR susceptibility locus on chromosome 4q. 
Clearly, the chromosome 4q locus has incomplete penetrance. Is this 4q locus solely 
leading to HSCR or alternatively, is the phenotype only expressed in the presence of other 
susceptibility loci? Modifier loci either can increase susceptibility and severity of the phenotype or 
can act protectively to confer resistance to the disease in the face of a predisposing mutation 40. 
Can variants within the RET gene explain the difference in penetrance observed in both branches? 
We investigated whether all patients shared a haplotype similar to the common risk haplotype 
defined by SNPs located in the 5’ region of the RET locus reported in Dutch HSCR patients 26. We 
identified non risk haplotypes in patients IV-3 and V-4. However, the spouse IV-1and the 3 affected 
children V-1, V-2, and V-3 were homozygote and heterozygotes, respectively, for the GATAG 
haplotype, which contains the core risk haplotype detected in European, and European-American 
patients with sporadic HSCR 27 28. The third and fourth SNPs (RET3+, rs2435357 and IVS1+9494, 
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rs2506004) are particularly interesting as disease-associated RET variants, because of the homology 
and evolutionary conservation between rodents and primates and the differences in allele/genotype 
frequencies among patients and controls 27. Recent data show that RET3+ might lie within, and 
might compromise the activity of an enhancer-like sequence in RET intron 1 28. These findings make 
us hypothesize that the 5’ RET risk haplotype in combination with the identified chromosome 4 
locus might play a role in penetrance and severity observed in the sibship with 3 affected children. 
We looked for candidate genes in the minimum 12.2 Mb-linked region at 4q31.3-32.3 
(between markers D4S3049 and D4S1566) in the human genome sequence. This region contains 
at least 57 genes, in accordance with the National Center for Biotechnology Information (NCBI) 
build 35.1 of the human genome and the Ensemble Genome Browser. The maximum 20-Mb 
linked region between D4S2962 and D4S1597 encompasses 93 genes, including several interesting 
functional candidate genes that are proposed to be involved in neural crest development or neuronal 
development.
Unfortunately, the maximum genetic interval contains far too many candidates to begin 
functional evaluation of each gene individually; the best positional and functional candidate we could 
identify is Mab21L2 (named after male abnormal 21 in C. Elegans). Mab21L2 is expressed in the 
central nervous system and neural crest in midgestation embryogenesis in mice 41. Furthermore, 
Mab21L2 is linked to the TGFbeta signaling pathway to which also ZFHX1B belongs 13, 42. ZFHX1B, 
the gene involved in Mowat-Wilson syndrome, a syndromic form of HSCR, is a transcription factor 
that functions as a transcriptional repressor 42. For these reasons we sequenced the complete 
coding region of the Mab21L2 gene for mutations; however we did not identify a sequence variant in 
Mab21L2. Besides Mab21L2, many other candidate genes are located in the region. Several proteins 
encoding neuropeptide Y receptors (NPY2R, NPY1R and NPY5R) are located in the minimum 12.2 
Mb-linked region. In mammals NPY, the ligand, is mainly found in cells derived from the neural 
crest, and is widely distributed in the central and peripheral nervous system 43. Furthermore, the 
gene for the secreted frizzled related protein 2 (SFRP2) is located in this region 44. Wnt-frizzled 
signaling is involved in neural crest formation 45.
The 4q locus may be necessary but not sufficient to cause HSCR in the absence of modifying 
loci elsewhere in the genome. Linkage analysis in additional multigenerational HSCR families and 
association studies in sporadic patients with high-density marker sets covering the entire interval 
will be necessary to confirm this suggestive linkage to chromosome 4q. Eventually, identification 
of the causative gene defect will specify the susceptibility to HSCR conferred by this novel locus at 
4q31.3-q32.3. 
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DISCUSSION
1. Strategies for finding genes for Hirschsprung disease susceptibility
To date only 30% of HSCR cases can be attributed to mutations in the coding sequences of 9 known 
HSCR susceptibility genes 1. The aim of our studies was to identify new genes involved in HSCR 
susceptibility by studying both syndromic and non-syndromic families segregating HSCR. To this 
end we have chosen the design of traditional linkage. 
Additional HSCR susceptibility genes likely are bound to be identified in the future. 
However, finding these genes might turn out to be difficult, because the individual effects might 
be small 2 3.This problem is inherent in studies designed to identify susceptibility loci for complex 
diseases 4. Yet one could think of plausible approaches to identify these HSCR susceptibility genes. 
Here strategies to identify genes involved in syndromic HSCR will be discussed, as well as possible 
approaches for the identification of non-syndromic HSCR susceptibility genes. 
1.1 Syndromic Hirschsprung disease
1.1.1 Rare autosomal recessive syndromes 
To identify genes involved in syndromic HSCR one could study rare presumptive Mendelian 
combinations of HSCR associated with additional major and/or minor congenital malformations. In 
general, mapping of genes involved in rare recessive syndromes is difficult because of the paucity of 
large families with enough affected progeny to provide sufficient statistical evidence for linkage. The 
alternative is using inbred affected families. 
We have chosen this latter strategy to identify by homozygosity mapping the gene involved 
in Goldberg-Shprintzen syndrome, a rare autosomal recessive disorder 5, 6 (chapters 2 and 3). The 
basic concept of this method is to use the information provided by a genome-wide scan in inbred 
affected individuals in order to define a region of the genome where they are all homozygous 
7. The disease locus is then highly likely to map in this region. Identification of the gene defect 
causing this rare and relatively simple Mendelian disorder in only 4 affected children from one 
consanguineous family using this robust method, underlines the high power of this study design. The 
use of homozygosity mapping in a genome-wide scan requires a set of regularly spaced markers, 
which is of course also a condition sine qua non in classical linkage studies in multigenerational 
families from outbred populations. Spacing of the markers (typically around 400 CA repeat markers 
with an average spacing of 10 cM), should be based on the notion that the pedigree structure 
determines the expected length of the region of identity by descent around the disease locus. In 
our initial screen with 381 markers, only one of the four affected individuals was homozygous by 
descent for two flanking markers at chromosome 10q, whereas the other three were homozygous 
for one of these two markers. Excluding a region by the criterion that all affected individuals in the 
sample are not homozygous may increase the rate of false negatives and the locus of interest is likely 
to be missed 8. More closely spaced STRPs (800 markers) or even high-density single-nucleotide 
polymorphism (SNP) genotyping arrays may be needed in extended pedigrees with low inbreeding 
coefficients 9. For these reasons the choice of the distance between adjacent markers is not a trivial 
matter. Furthermore, the threshold criterion for exclusion of a region should be defined according 
to the specific family structure and the number of available affected family members.
 
1.1.2 De novo dominant syndromes
Gene finding in sporadic syndromic HSCR cases consistent with a de novo autosomal dominant trait 
requires other methods to identify the underlying defect. In the absence of patients with chromosomal 
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aberrations detectable by conventional G-banding (resolution 5-10 Mb), high-resolution techniques 
such as array Comparitive Genomic Hybridization (array-CGH)  10, oligo-microarray 11, or SNP 
arrays 12 might be instrumental to detect small deletions or duplications in those sporadic patients 
with a combination of HSCR, mental retardation and additional multiple congenital malformations. 
The most common technique uses a BAC array that covers the complete human genome with 1-
Mb resolution 13. Tiled (i.e. overlapping) BAC arrays have now become available with even higher 
resolution 14 and promising diagnostic yield 15. The identification of a deletion by this technique might 
represent a promising starting point for further positional cloning experiments as was recently 
successfully demonstrated in patients with CHARGE syndrome (OMIM 214800) 16 and as was 
suggested in patients with syndromic congenital diaphragmatic hernia 17. 
This approach is of course only effective if one assumes that not only intragenic mutations 
occur, but also microdeletions encompassing the underlying gene defect. This strategy is of particular 
interest for those sporadic syndromes that cannot be tackled by other mapping methods because 
of limited reproductive fitness often associated with mental retardation. In particular, one group 
of syndromic HSCR cases that might be studied with this approach is the group of HSCR-mental 
retardation-microcephaly cases unrelated to the known loci on 2q22 18 or 10q22.1 (chapter 4). 
Syndrome delineation and molecular studies are essential in this group of HSCR patients 
to further unravel the biological relationship between enteric nervous system and central nervous 
system development. This entity seems clearly to be heterogeneous. This genetic heterogeneity 
might reflect interactions at the protein level, such as ligand-receptor interactions, different subunits 
of a multiprotein complex or proteins that function at different steps of a pathway 19. All three 
interactions are already known to exist in HSCR: GDNF-RET and EDN3-EDNRB are examples of 
ligand-receptor interactions, GDNF-GFRalfa functions as a multiprotein complex and EDN3-ECE1 
represents the ligand and its cleavage enzyme 20-25. Using expression arrays 26 to identify common 
affected pathways and integrating this knowledge with e.g. the data obtained with genomic array 
studies could lead more directly to the identification of the candidate gene(s). 
1.2 Non-syndromic Hirschsprung disease 
1.2.1 Linkage analysis
Linkage analysis is feasible in extended multigenerational families or multiple small nuclear families in 
which genetic homogeneity is assumed. If successful, linkage can identify a sometimes large genomic 
region, often containing many genes, in which the disease gene is sought. First of all one could 
collect familial cases with non-syndromic HSCR following a (presumptive) Mendelian inheritance 
pattern for gene mapping studies that might lead to the identification of putative HSCR susceptibility 
loci. Before a genome wide mapping procedure can be started, a thorough clinical diagnosis is 
required. In search of genes for HSCR susceptibility, only family members with histologically proven 
aganglionosis should be indicated as affected and not those who report constipation. Since RET is 
the major gene involved in HSCR susceptibility in multigenerational families 27, mutations in the 
coding sequence of RET and linkage to RET should be first excluded before starting gene mapping 
studies in suitable families. These linkage approaches might replicate or exclude the regions on 3p21, 
9q31, 19q12 and 16q23 that were previously found to be implicated on the basis of genetic linkage 
and association studies 27-29. Identification of additional large families might eventually confirm the 
localization of these putative HSCR susceptibility loci and hopefully delineate smaller regions of 
interest, or might identify new chromosomal regions associated with HSCR. 
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A genome-wide linkage analysis in a 5-generation pedigree with 5 family members presenting 
with isolated HSCR allowed us to identify a new locus with a lowered penetrance at 4q31.3-q32.3 
(chapter 6). The result of this study underlines one of the problems of a traditional linkage design; the 
shared haplotype in the 5 affected family members extends around 12.2 Mb on the NCBI physical 
map and encompasses many genes. Unfortunately, the region is too large for mutational screening 
of every gene located in the region of interest. Importantly, the statistical analysis of such kind of 
families should allow for uncertainties related to the correct genetic model. Non-syndromic HSCR 
was proven to be an oligogenic inherited congenital malformation determined by a small number of 
genes acting together 27, 28. Therefore, both parametric and non-parametric or model-free linkage 
analyses should preferably be performed. 
1.2.2 Association analysis
As not many HSCR families with multiple affected individuals are available for linkage studies, a better 
approach seems screening of a dense set of SNPs (e.g. one SNP every 5 kb) confined to the regions 
implicated by initial low-resolution linkage studies 28-30, for regional association and transmission 
studies in siblings or sporadic patients in a trio design. This can be done by linkage disequilibrium 
(LD) mapping 3; this implies a non-random association between a pair of markers. LD is common 
for markers that are located close to another. The presence of LD between SNP markers makes it 
possible to infer the location of a disease gene that is in LD with a genotyped SNP. The optimal SNP 
density for these studies is dependent on the extent of local LD 3. The extent of LD determines the 
size of the shared ancestral haplotypes; the more time has elapsed since a mutation was introduced 
in the population, the more likely an ancestral haplotype has been disrupted by a recombination 
event, reducing the extent of LD and the size of the shared haplotype. This step is aimed at reducing 
as much as possible the size of the critical region, leaving a small number of candidate genes. This 
strategy has a higher resolution than linkage analysis in families; however, large patient cohorts are 
still needed.  
1.2.3 Candidate genes 
The identification of genes involved in non-syndromic HSCR might focus on candidate genes. 
Candidate genes could be selected on the basis of (1) expression within the tissue of interest, 
(2) functional criteria, such as membership of a known disease pathway, or (3) localization to an 
implicated chromosomal region, on the basis of previous linkage studies.  For example, concerning 
the development of the enteric nervous system, genes involved in neural crest development might 
represent possible functional candidate genes. Of interest is the list of genes highly expressed in 
gut neural crest stem cells described by Iwashita and others 31. Gene expression in gut neural crest 
stem cells from rat was compared with expression in the whole-fetus (E14.5). Genes that have been 
linked to HSCR are frequently expressed at higher levels in gut neural crest stem cells. Of the 10 
known genes that are  most highly expressed in gut neural crest stem cells relative to whole-fetus, 
mutations in 4 (RET, SOX10, GFRA-1 and EDNRB) have been implicated in HSCR. Consequently, the 
remaining genes that are more highly expressed in gut neural crest stem cells relative to whole–
fetus, make up a list of candidate genes on the basis of expression within the tissue of interest.    
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2. The newly identified KIAA1279 gene at chromosome 10 and the non-
syndromic Hirschsprung disease locus at chromosome 4
2.1 KIAA1279
By identifying KIAA1279 as the gene involved in GOSHS, we have proven that not only clinically 
but also genetically MWS and GOSHS are two separate conditions 32. Apart from RET, KIAA1279 is 
the second gene at the long arm of chromosome 10 involved in HSCR susceptibility. While RET is 
the major gene in non-syndromic HSCR, KIAA1279 mutations are only found in a selected group of 
syndromic HSCR patients (chapters 3 and 4).
After fine mapping, a region of 2.8 Mb was identified at the long arm of chromosome 10 
for which all patients were homozygous. All 30 transcripts located in this region were screened. In 
retrospect we wondered if we could have prioritized the order of most likely positional candidates 
by a tool other than searching the literature. The combination of gene mapping data with genetic 
expression profiling, which measures the expression levels of many genes at once 26, might provide a 
good option to select candidates 33. This strategy might have been especially reasonable afterwards, 
since the mutations identified in KIAA1279 were both nonsense mutations. This could mean that the 
mutant messenger RNAs trigger the nonsense mediated decay RNA surveillance pathway, which in 
turn degrades only transcripts containing nonsense codons that are followed by at least one intron 
34. What is more,  one third of human disease genes are predicted to result from nonsense lesions 
or mutations that decrease transcript abundance 35 36.  Expression profiling studies in fibroblasts of 3 
affected GOSHS individuals from the Moroccan family showed that KIAA1279 was among a set of 20 
genes with significantly decreased expression. Furthermore, KIAA1279 was the only gene/transcript 
identified as having reduced expression in our region of interest (personal communication Van der 
Spek and Mancini). In this respect, integrating the expression microarray analysis and the linkage 
data would have led directly to the identification of the gene. Genetic expressing profiling may 
therefore represent a powerful tool in picking the right candidate genes and may dramatically speed 
up sequencing efforts and facilitate positional cloning approaches.  
As patients with MWS and GOSHS have partly overlapping phenotypes (including 
malformations of cortical brain development in a set of patients) 32, 37, overlap at the molecular level 
is likely as well . The mechanisms underlying the phenotypic effects of a ZFHX1B mutation have not 
been fully determined. Interestingly, ZFHX1B mRNA is detected in nearly all human tissues (like 
is the case for KIAA1279) as well as mouse heart and brain. ZFHX1B expression is also detected 
in fetal human tissues including brain, kidney, liver, and spleen 38, 39. Mouse Zfhx1b is expressed 
in many brain regions (hypothalamus, cerebellum, cortex, rhombencephalon, hippocampus, mid 
brain, and spinal cord) 40. It would be of interest to see whether the expression patterns of mouse 
Kiaa1279 and Zfhx1b overlap and to see whether both proteins could have critical functions in 
vertebrate neural crest and cortex development during embryogenesis. The function of KIAA1279 
is still unknown. Although this gene has probably no role in sporadic isolated HSCR or isolated 
polymicrogyria (chapter 4), the importance of this rare gene defect might lie in the identification of 
a pathogenic pathway. Further studies need to ascertain the function of KIAA1279 and characterize 
the protein network in which KIAA1279 acts. 
Besides the fact that KIAA1279 is highly conserved and expressed in specific tissues, we 
know that the protein contains two tetratrico peptide repeats (TPR), a structural motif consisting 
of 34 amino acid residues, in exon 1/2 and exon 4, respectively. Because of these repeats, KIAA1279 
may be considered a member of the TPR protein family. The most basic function of TPR motifs 
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is to mediate protein-protein interactions 41. Proteins with TPR motifs are involved in a variety 
of biological processes, such as cell cycle regulation, transcriptional control, mitochondrial and 
peroxisomal protein transport, neurogenesis and protein folding. 
A first possible indication of the function of KIAA1279 is derived from the investigation of 
the subcellular localization of the protein; antibody staining in HeLa cells showed that the KIAA1279 
protein is localized in the cytoplasm (De Graaff; unpublished results). These preliminary data 
can be used as a starting point to identify the protein network in which KIAA1279 functions. The 
speculation would be that genes encoding these proteins are involved in related phenotypes, and 
that in this way clinical classification precedes molecular verification 19. Therefore, functional studies 
of KIAA1279 are hoped to provide more knowledge on the molecular basis of GOSHS, HSCR, and 
polymicrogyria- a disorder of cortical organization- as well, for which only a few genes and loci have 
been identified so far (for a review see Jansen and Andermann) 42, 43. 
Study of these proteins will provide us with a window through which we can observe 
the development of both human cortex and enteric nervous system. Hopefully it will answer 
the questions why HSCR can be associated with microcephaly and/or malformations of cortical 
brain development and whether the underlying neurodevelopmental process is caused by either 
defective neuronal mitosis or defective neuron migration. The former was recently hypothesized 
for autosomal recessive inherited primary microcephaly, characterized by a substantial reduction 
in the size of the cerebral cortex, but with a normal architecture 44; the latter for lissencephaly, a 
disorder of cortical brain development characterized by a smooth or agyric brain 45. Since HSCR 
is generally regarded as a migration disorder of precursors derived from the vagal neural crest 46, 
an attractive hypothesis would be that HSCR and malformations of cortical brain development 
in GOSHS are the consequence of disturbed neuronal migration of vagal neural crest cells and 
of progenitor cells of the cerebral cortical neurons, respectively. A possible role of KIAA1279 in 
neuron proliferation (that is mitosis of the progenitor cells of the cerebral cortical neurons) during 
fetal life and/or neuronal migration will be object of further studies. 
 
2.2. Chromosome 4 locus
We provided suggestive evidence for a fourth locus that could be involved in non-syndromic HSCR 
apart from the previously reported three loci at 3p21, 9q31 and 19q12 27, 28. Clinically this HSCR 
susceptibility locus seems to be representing a susceptibility locus with a lowered penetrance in the 
described family. In our genome-wide search no other regions were identified, however the low 
penetrance in this family is likely to be related to additional genes with low effects. We hypothesized 
that a 5’RET risk haplotype, similar to the common ancestral haplotype present in HSCR patients 
worldwide47, 48, in combination with the identified chromosome 4 locus might be involved in the 
high disease penetrance and severity observed in one branch of this multigenerational family. 
Our suggestive evidence for linkage at chromosome 4 first needs to be confirmed in independent 
families, otherwise immense sequence efforts to identify the underlying gene might be without 
positive results.
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3. The genetics of syndromic and non-syndromic Hirschsprung disease: 
Implications for Syndrome Diagnosis and Genetic Counseling 
Since roughly 1 in 3 HSCR cases has additional congenital malformations, depending on the diligence 
with which they are sought 49-51, every child diagnosed with HSCR should at least once be seen by a 
geneticist-dysmorphologist to rule out recognizable patterns of malformations 52. Sixty-six entries 
including HSCR as a clinical feature have been described in the London Dysmorphology database 
and 52 in the Australian POSSUM. 
Lyonnet and Amiel divided HSCR-associated syndromes in 4 groups: (1) neurocristopathy 
syndromes, (2) syndromes with HSCR as a mandatory feature, (3) occasional or rare associations 
with recognizable syndromes, and (4) miscellaneous observations 49. The clinical observation of 
specific entities with HSCR as a major feature in combination with a myriad of malformations 
related to the neural crest, suggested a molecular link between these neural crest derivatives 
hypothesized in 1974 by Bolande 53. The identification of the genes EDNRB 23, EDN3 21, 54 and SOX10 
55 involved in Shah-Waardenburg syndrome (OMIM 277580), proved that the hypothesized concept 
of neurocristopathies of Bolande indeed has a molecular basis. Thus, group 1 indeed represents a 
distinctive group of HSCR patients and should make the clinician aware of the possible presence of 
neural crest related features in every HSCR patient (e.g. neuroblastoma risk in HSCR cases with 
specific PHOX2B mutations) 56. Group 2 (syndromes with HSCR as a mandatory feature) represents 
a much more diverse group of HSCR patients. GOSHS is categorized into this group. However, 
our studies have shown that HSCR is actually a major, albeit not a mandatory feature of GOSHS 
(chapters 2 and 4). It is barely understood why HSCR occasionally occurs in the syndromes grouped 
in category 3, such as the genetically heterogeneous Bardet-Biedl syndrome (OMIM 209900) 
(chapter 5) or the metabolic Smith-Lemli-Opitz syndrome (OMIM 270400) 57-60 One therefore 
could only speculate that cholesterol metabolism 61, 62 and cilia dysfunction 63 are somehow related 
to ENS development, which would explain the occurrence of HSCR in some, but not all cases with 
Smith-Lemli-Opitz syndrome or Bardet-Biedl syndrome, respectively. The variety of syndromes 
associated with HSCR implies considerable genetic heterogeneity in the etiology of HSCR although 
some of these syndromic associations may be due to chance, especially in group 4 of miscellaneous 
observations. 
In anticipation of the unravelling of the genetic background of these syndromes, a 
classification system of syndromic forms of HSCR based on defined developmental pathways 
(i.e. grouping of clinical disorders by pathway), gene families, or biochemical processes might be 
preferable. 
This classification system could be proposed for every multiple malformation syndrome 64. In 
case of syndromic HSCR, patients might be categorized in disorders related to (1) the glial cell-
derived neurotrophic factor signaling pathway (RET related HSCR/MEN2A), (2) the endothelin 
signaling pathway (EDNRB, EDN3,  ECE1 related cases), (3) the transforming growth factor β signaling 
pathway (ZFHX1B), and (4) the sonic hedgehog signaling pathway (HSCR related to Smith-Lemli-
Opitz syndrome) (see table 1). The syndromes that cannot be placed within a specific pathway 
are grouped according to either (5) the gene families to which the responsible genes belong (e.g. 
GOSHS related to KIAA1279 mutations might be categorized as a syndrome caused by a member 
of the TPR protein family) or (6) the processes or functions in which the genes are involved (e.g. 
microtubule motors in case of HSCR related to Bardet-Biedl syndrome or transcription factors in 
case of SOX10 and PHOX2B). Finally (7) a remaining group should be composed of syndromic HSCR 
cases without a known gene defect so far. We realize that our attempt to classify syndromic HSCR 
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cases into these 7 groups is imperfect and also liable to changes in the future. For instance, as the 
function of KIAA1279 will be unravelled, GOSHS will most likely be categorized in another (new) 
group of syndromes. The grouping will benefit if a worldwide register will be set up for all the HSCR 
cases with or without a molecular diagnosis.          
Although knowledge of the genes involved in HSCR susceptibility and the molecular processes 
involved in ENS development has grown rapidly over the past years, the impact of this knowledge 
is still relatively modest in clinical practice. One can question the benefit to the individual patient 
of testing for mutations predisposing to HSCR. In the Netherlands, genetic diagnostic testing is 
available for RET, EDNRB, EDN3 and SOX10. To date, in our laboratory, 40 mutations of these 4 
genes have been found among a total of approximately 250 HSCR cases (personal communication 
R.M.W. Hofstra). One reason for genetic testing of HSCR patients is to exclude the rare possibility 
of a MEN2A associated RET mutation which carries an elevated risk for MTC 65. 
Another reason for genetic testing could be to give more accurate estimation for recurrence 
risks to parents of a HSCR patient. For example the finding of a pathogenic RET mutation in a male 
proband with L-HSCR and the exclusion of this mutation in the parents may lower the recurrence 
risk from13-17% to less than 1%, taking into account the theoretical possibility of a mosaic germ 
line mutation in one of the parents. The risk evaluation in this particular case is only justified by the 
assumption that RET is the major gene in HSCR development. We are not aware of requests for the 
prenatal diagnosis of a RET mutation with the aim of elective termination of the pregnancy, when a 
mutation was known to segregate in the family. This is probably related to the variable expression 
and incomplete penetrance of RET mutations and the good prognosis after surgical intervention in 
the majority of HSCR patients 66. However, in our limited experience, parents who have lost a child 
with total intestinal aganglionosis or parents of syndromic HSCR cases (e.g. GOSHS) want to discuss 
options for prenatal diagnosis. In the absence of genetic testing and until all the genes involved in 
Defined Pathways Genes Syndromes
1 GDNF signaling RET MEN2A-HSCR 
2 Endothelin signaling EDNRB, EDN3 Shah-Waardenburg syndrome
3 Sonic-hedgehog signaling DHCR7 Smith-Lemli-Opitz syndrome
4 TGF-β signaling ZFHX1B Mowat-Wilson syndrome
5 Gene family
TPR KIAA1279 Goldberg-Shprintzen syndrome
6 Gene function
Microtubule motors BBS genes Bardet-Biedl syndrome, Kaufman-
McKusick syndrome
Transcription factors SOX10, 
PHOX2B
Shah-Waardenburg syndrome
PCWH syndrome
Haddad syndrome
7 Remaining group ?
Table 1. Proposed classification of syndromes associated with HSCR
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HSCR genesis are elucidated, the risk estimation can be calculated from the segregation analysis by 
Badner 67. At present the common risk RET haplotype 47 has no clinical implications; risk assessment 
by genetic risk profiling is not feasible because of unknown additional risk factors in HSCR.   
Routine screening of the 10 known genes in every HSCR patient is time-consuming, 
expensive (the current cost for DNA diagnostics is 640 euro per gene in the Netherlands) and 
has a limited yield. We, therefore, propose the following guidelines for the practicing pediatrician, 
pediatric surgeon or clinical geneticist when dealing with a patient with HSCR. Both in non-syndromic 
sporadic (especially LS-HSCR) and familial HSCR cases, routine RET mutational screening is feasible 
68. However, before sampling and mutational analysis take place, genetic counseling should also 
address the issue of the co-occurrence of MEN2A and HSCR in occasional families 65 and how to 
deal with the follow-up when a MEN2A related RET mutation is identified 69. Oncological and genetic 
counseling should always complement the management of such affected families. Routine screening 
of GDNF and Neurturin, both encoding ligands of the RET protein and therefore considered plausible 
functional candidates, is not indicated since these genes are mutated only rarely 70, 71. Routine 
mutational screening of EDNRB in sporadic isolated HSCR cases should be considered, since it is the 
second most mutated gene in this group 72-74.
A scheme showing which genes to test for mutations in HSCR patients with and without additional 
malformations and dysmorphisms is proposed (fig 1).
When a patient has additional abnormalities that can be classified as neural crest related (pigmentary 
abnormalities such as heterochromia of the irises, a white forelock, or sensorineural deafness) 
testing for EDNRB and EDN3 mutations is justified. Shah-Waardenburg patients with an extended 
PAP= postaxial polydactyly, OFC=occipito-frontal circumference, 
PMR=psychomotor retardation; MCD=malformation of cortical development, 
CHD= congenital heart defect 
7DHC= 7-dehydrocholesterol (cholesterol precursor) 
HSCR patient
 
Small OFC
 
PMR
 
Deafness  
Poliosis  
Heterochromasia 
Autonomic  
Dysregulation  
 
Central 
Hypoventilation  
KIAA1279 ZFHX1B 
Neurologic 
SOX10  PHOX2B  EDNRB
   
ECE1 
EDN3 
CHDMCD
7DHC 
RET/EDNRB  
PAP  
BBS
Figure 1
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neurological phenotype (e.g. a neuropathy) should be tested for mutations in SOX10 55, 75. This 
latter phenotype is designated as PCWH (OMIM 609136); peripheral demyelinating neuropathy, 
central dysmyelinating leukodystrophy, Waardenburg syndrome, and HSCR 76. When symptoms of 
autonomic nervous system dysregulation including congenital central hypoventilation are diagnosed 
77, PHOX2B mutation analysis is advisable 78. It is estimated that up to 30% of HSCR patients may 
have some form of dysautonomia 79 and approximately 1.5% of HSCR patients will have Congenital 
Central Hypoventilation Syndrome or Haddad syndrome (OMIM 209880).  PHOX2B mutation 
analysis is also warranted in HSCR-neuroblastoma cases 56, 80. Interestingly, analysis of genotype-
phenotype interactions strongly supported the contention that patients with Congenital Central 
Hypoventilation Syndrome who develop malignant tumours of the sympathic nervous system will 
harbor either a missense or a frameshift heterozygous mutation instead of a  polyalanine expansion 
mutation of the PHOX2B gene 56. Pediatric surgeons should be aware of this specific association and 
may be alerted to perform strict follow-up protocols in this subgroup of HSCR patients (screen 
catecholamines in suspected neuroblastoma) 81.   
Screening of ZFHX1B and KIAA1279 is indicated in every HSCR patient with microcephaly 
and/or mental retardation. Without the help of pedigree information consistent with a clear-cut 
autosomal recessive inheritance discriminating between these 2 syndromes/genes might be difficult 
in a young child 82-84. Clearly, additional minor facial features might help to decide which gene should 
be screened first. While high arched eyebrows are consistent with mutations in KIAA1279 (chapters 
2 and 4), the configuration of the eyebrows is horizontal and shows medial flaring in Mowat-Wilson 
syndrome 18, 85, 86. Furthermore epilepsy is frequently reported in Mowat-Wilson cases18, but so far 
it has been reported only once in our case series of patients with mutations in KIAA1279 (chapter 
4). We have proven that HSCR in GOSHS is a major, yet not a mandatory feature (chapter 4). 
Now the KIAA1279 gene has been found to be associated with this syndrome, a clearer picture will 
emerge of what constitutes the core phenotype and its variants (chapter 3).  We propose that a 
malformation of cortical development (diffuse polymicrogyria or a simplified gyral pattern) might 
be part of the core phenotype, but that this feature is probably underreported because of the lack 
of detailed MRI studies in all microcephalic or retarded HSCR cases (chapter 4). Therefore, the 
recommendation would be that every child with HSCR and mental retardation and/or microcephaly 
is referred to a pediatric neurologist and that an indication for MRI of the brain is established. Given 
the fact that Smith-Lemli-Opitz syndrome cases might also present with HSCR and microcephaly, 
plasma cholesterol levels should be measured in these cases. The facial Gestalt is striking; apart 
from microcephaly, Smith-Lemli-Opitz patients have bilateral ptosis, a broad and high forehead, a 
long philtrum and anteverted nares. These typical facial features together with structural defects of 
internal organs (e.g.HSCR) make that experienced dysmorphologists will recognize Smith-Lemli-
Opitz patients easily.  
The combination of postaxial polydactyly (PAP) and HSCR warrants a careful clinical 
follow-up during childhood; these children may develop retinopathy and represent Bardet-Biedl 
syndrome. Therefore, in a limited number of HSCR cases with PAP, screening of the BBS genes 
is advisable (chapter 5), especially in those cases with other features such as renal abnormalities 
and learning disabilities. However, because of the extensive genetic heterogeneity of Bardet-Biedl 
syndrome, mutation analysis will often be restricted to BBS genes involved in specific ethnic groups 
(e.g. BBS1 screening in Caucasians) 63, 87.      
Although an ECE1 mutation was reported only once so far 22, one might consider ECE1 
mutational analysis in a HSCR patient with a complex heart defect after exclusion of a 22q11.2 
deletion by FISH 88. 
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Provided that fruitful collaborations between departments of clinical genetics and pediatric surgery 
continue, HSCR patients in the coming years will benefit from further elucidation of the genes involved 
in HSCR susceptibility. Identification of these genes is of major importance for disease prognosis 
and accurate genetic counseling. Finally, a complete understanding of the genetic mechanisms that 
restrain the development of the ENS could have a major impact on clinical practice.
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Summary
In Chapter 1, the genetic aspects of Hirschsprung disease are reviewed. With a prevalence of one in 
5000 live born children, Hirschsprung disease is the most frequent cause of bowel obstruction in 
childhood, and it occurs worldwide. Neonates born with Hirschsprung disease are unable to pass 
their first stool, and as a consequence their bowels get distended (“congenital megacolon”). This 
congenital malformation is characterized by the absence of groups of neurons or nerve cells in the 
bowel wall. The role of inheritance in Hirschsprung disease was indicated by familial occurrence, 
male predominance (boys are affected four times as often as girls), the association with chromosomal 
aberrations such as trisomy 21, and a myriad of inherited syndromes caused by single gene defects. 
The search for genes involved in Hirschsprung disease has been successful; so far 9 genes (RET, GDNF, 
Neurturin EDNRB, EDN3, ECE1, SOX10, ZFHX1B, and PHOX2B) had been implicated in Hirschsprung 
disease. RET proved to be the major gene involved in Hirschsprung disease susceptibility. These 9 
genes, however, do not explain the  majority of patients with Hirschsprung disease yet.
The aim of our studies was to identify new genes or loci involved in Hirschsprung disease 
susceptibility by studying non-syndromic as well as syndromic Hirschsprung disease families, 
treated at the Pediatric Surgery Department of the Erasmus MC-Sophia Children’s Hospital. Part 1 
of this thesis (chapters 2-5) concerns the clinical and molecular characterization of families in which 
Hirschsprung disease is associated with additional congenital malformations. Chapter 2 describes 
the study of a consanguineous Moroccan family with a rare autosomal recessive form of syndromic 
HSCR, Goldberg-Shprintzen syndrome. First described by Robert Shprintzen and Rosalie Goldberg 
in 1981 in a brother and a sister, this syndrome is characterized, apart from Hirschsprung disease, 
by mental retardation, a small head circumference (microcephaly) and typical facial features (e.g. 
high-arched eyebrows). We showed that Hirschsprung disease is a major, albeit not a mandatory 
feature of Goldberg-Shprintzen syndrome. We suggested that this inbred Moroccan family might be 
instrumental to identify the Goldberg-Shprintzen gene.     
  In Chapter 3 we performed a genome-wide scan and homozygosity mapping in the 
consanguineous Moroccan family with Goldberg-Shprintzen syndrome. The family was considered 
suitable for homozygosity mapping. The basic concept of this method is to use the information 
provided by a genome-wide scan in inbred affected individuals in order to define a region of the 
genome where they are all homozygous. This homozygous region likely contains the mutated 
gene causing the disease. We demonstrated homozygosity of 10q22.1 and successively identified 
a homozygous truncating mutation in KIAA1279 gene, one of the 30 genes located in this shared 
homozygous region. Identification of the gene defect causing this rare disorder in only 4 affected 
children from one family, underlined the high power of this study design. Since bilateral generalized 
polymicrogyria (a developmental disorder of the cerebral cortex or grey matter of the brains) was 
diagnosed in all patients in this family, we proposed that this feature might be considered a key 
feature of the syndrome.
Chapter 4 focused on the phenotypic diversity of KIAA1279 mutations. We identified 
mutations in 3 new Goldberg-Shprintzen syndrome families. No KIAA1279 mutations were identified 
in 26 sporadic, non-syndromic patients with Hirschsprung disease, in 14 individuals that were 
initially diagnosed as possible Mowat-Wilson syndrome cases or in 6 cases with polymicrogyria. 
Hirschsprung disease occurred in 81% of the affected cases with Goldberg-Shprintzen syndrome. 
Importantly, MRI studies of the eldest Goldberg-Shprintzen patient known to be alive to date 
showed a simplified gyral pattern and diffuse white matter loss. We concluded that malformations 
of cortical development represent core features of Goldberg-Shprintzen syndrome. Consequently, 
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we recommended that every child with Hirschsprung disease and mental retardation and/or 
microcephaly be referred to a pediatric neurologist and undergo brain MRI. Neurological and 
ophthalmologic complications might develop later; all older children showed progressive scoliosis 
and corneal infections. Follow-up of the original two cases reported by Goldberg and Shprintzen 
confirmed this observation. Since not all Hirschsprung disease cases associated with microcephaly 
and mental retardation can be attributed to mutations in KIAA1279 or ZFHX1B, there must exist 
other genes whose mutations can lead to this specific combination of features. 
Chapter 5 entailed clinical and molecular studies in a family with a sister and a brother 
affected with the combination of Hirschsprung disease and a syndrome representing McKusick-
Kaufman syndrome or Bardet-Biedl syndrome. Both are rare autosomal recessive syndromes with 
overlapping clinical and molecular spectrum. Sequencing 3 of the 9 genes BBS genes did not reveal 
any mutations. Mutation scanning of RET, revealed a sequence variant Lys716Asn in the affected 
girl, but not in the affected brother. It is uncertain whether this variant contributes to Hirschsprung 
disease in this family.  
 Part 2 of the thesis (Chapter 6) is concerned with non-syndromic or isolated Hirschsprung 
disease. In Chapter 6 the study of a multigenerational family with Hirschsprung disease segregating 
in two main branches, allowed us to provide suggestive evidence for the existence of a novel 
Hirschsprung susceptibility locus on chromosome 4q. We speculated that the penetrance in this 
family might be RET-dependent.
Chapter 7 is a general discussion on strategies for finding genes for Hirschsprung disease 
susceptibility and on our findings. Additional Hirschsprung disease susceptibility genes might be 
identified in the future, although the search for these genes might turn out to be difficult as the 
individual effects might be small.
Identification of the genes involved in Hirschsprung disease is of major importance for disease 
prognosis and accurate genetic counselling. As routine screening of the current genes known 
to be involved in Hirschsprung disease is not feasible, we propose guidelines for the practicing 
pediatrician, pediatric surgeon or clinical geneticist when dealing with a patient with Hirschsprung 
disease. Furthermore, a classification system based on defined developmental pathways for 
syndromes associated with Hirschsprung disease is proposed. Provided that fruitful collaborations 
between departments of clinical genetics and pediatric surgery continue, HSCR patients in the 
coming years are bound to benefit from further elucidation of the genes involved in Hirschsprung 
disease susceptibility.
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Samenvatting
In Hoofdstuk 1 (Introduction) wordt een overzicht gegeven van de genetische aspecten van de 
ziekte van Hirschsprung. De ziekte van Hirschsprung is wereldwijd de meest frequente oorzaak van 
een darmobstructie op de kinderleeftijd; de frequentie wordt geschat op 1:5000 levendgeborenen. 
Kinderen die met de ziekte van Hirschsprung worden geboren, hebben vaak een vertraagde 
meconiumlozing, en dientengevolge ontstaat er een bolle buik met uitgezette darmen (“congenitaal 
megacolon”). Deze aangeboren aandoening wordt gekenmerkt door de afwezigheid van 
ganglioncellen (groepen van neuronen) in de darmwand. Vele factoren wezen erop dat erfelijkheid 
een rol speelt bij het ontstaan van de ziekte van Hirschsprung; het optreden van de ziekte van 
Hirschsprung bij meerdere leden van een familie, het feit dat jongens vier maal zo vaak aangedaan 
zijn dan meisjes, de associatie met chromosoom afwijkingen (bijvoorbeeld trisomie 21) en tal van 
monogene syndromen. De zoektocht naar genen betrokken bij de ziekte van Hirschsprung is zeer 
succesvol gebleken; tot nog toe kon worden aangetoond dat 9 genen (RET, GDNF, Neurturin EDNRB, 
EDN3, ECE1, SOX10, ZFHX1B, en PHOX2B) betrokken zijn. Van het RET gen is bewezen dat het de 
belangrijkste genetische aanlegfactor is voor de ziekte van Hirschsprung. Echter, mutaties in deze 9 
genen, verklaren slechts een fractie van alle patiënten. 
Ons onderzoek had als doel om nieuwe genen of loci betrokken bij de ziekte van 
Hirschsprung te identificeren, door zowel families met niet-syndromale als syndromale vormen 
van de ziekte van Hirschsprung te bestuderen. De kinderen met de ziekte van Hirschsprung uit 
deze families werden behandeld op de afdeling kinderchirurgie van het Sophia Kinderziekenhuis/
ErasmusMC te Rotterdam. Deel 1 van dit proefschrift (Hoofdstukken 2-5) omvat de klinische en 
moleculaire karakterisering van families waarin de ziekte van Hirschsprung voorkomt met andere 
aangeboren afwijkingen. In Hoofdstuk 2, wordt een consanguine Marokkaanse familie met het 
Goldberg-Shprintzen syndroom, een zeldzame autosomaal recessieve syndromale vorm van 
de ziekte van Hirschsprung, beschreven.Dit syndroom werd voor het eerst beschreven bij een 
broer en een zus door Robert Shprintzen en Rosalie Goldberg in 1981. Het Goldberg-Shprintzen 
syndroom wordt niet alleen gekenmerkt door de ziekte van Hirschsprung, maar ook door een 
ontwikkelingsachterstand, een kleine schedelomtrek (microcefalie) en opvallende gelaatskenmerken 
(waaronder hoog-gebogen wenkbrauwen). Wij toonden aan dat de ziekte van Hirschsprung een 
belangrijk, echter geen obligaat kenmerk is van het Goldberg-Shprintzen syndroom. Wij meenden 
dat genetisch onderzoek in deze bloedverwante familie zou kunnen leiden tot de identificatie van 
het genetische defect in het Goldberg-Shprintzen syndroom.
In Hoofdstuk 3 verrichtten wij een scan van het genoom en homozygotie mapping in de 
consanguine Marokkaanse familie, beschreven in Hoofdstuk 2. Vanwege de bloedverwantschap tussen 
de ouders van de aangedane kinderen, meenden wij dat deze familie geschikt was voor homozygotie 
mapping. Het basisprincipe van deze methode is dat men gebruik maakt van de informatie verkregen 
uit de scan van het genoom bij aangedane kinderen van ouders die bloedverwant zijn, om zo een 
regio in het genoom af te bakenen waar alle patiënten homozygoot zijn. Deze overeenkomende 
homozygote regio bevat dan zeer waarschijnlijk het gen met de mutatie welke tot de ziekte heeft 
geleid. Wij toonden aan dat alle patiënten homozygoot waren voor een deel van chromosoom 10 
(10q22.1). Vervolgens identificeerden wij een homozygote truncerende mutatie in KIAA1279, één 
van de 30 genen in de homozygote regio. Het feit dat het mogelijk was om met slechts 4 aangedane 
kinderen afkomstig uit 1 familie het genetische defect op te sporen, illustreerde de kracht van deze 
studie opzet.
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Aangezien bilaterale gegeneraliseerde polymicrogyrie (een ontwikkelingsstoornis van de cerebrale 
cortex of grijze stof van de hersenen) in alle patiënten van deze familie werd gediagnosticeerd, 
meenden wij dat dit mogelijk een hoofdkenmerk van het syndroom betrof.
Hoofdstuk 4 is gericht op de fenotypische diversiteit van KIAA1279 mutaties. Wij 
identificeerden mutaties in 3 nieuwe families met het Goldberg-Shprintzen syndroom. KIAA1279 
mutaties werden niet aangetoond bij 26 sporadische niet-syndromale patiënten met de ziekte van 
Hirschsprung, noch bij 14 kinderen bij wie eerder het Mowat-Wilson syndroom werd vermoed, 
noch bij 6 kinderen met polymicrogyrie. In de families met het Goldberg-Shprintzen syndroom 
en een KIAA1279 mutatie, had 81% van de patiënten de ziekte van Hirschsprung. Van belang was 
dat MRI onderzoek van de hersenen bij de oudst levende patiënt met het Goldberg-Shprintzen 
syndroom, een “simplified gyral pattern” en een diffuus verlies van witte stof liet zien. Wij 
concludeerden dat malformaties van de ontwikkeling van de hersenschors hoofdkenmerken zijn 
van het Goldberg-Shprintzen syndroom. Om die reden, adviseren wij dat elk kind met de ziekte 
van Hirschsprung en een ontwikkelingsachterstand en/of microcefalie, verwezen wordt naar 
een kinderneuroloog en dat MRI onderzoek van de hersenen wordt verricht. Neurologische en 
oftalmologische complicaties ontstaan mogelijk op oudere leeftijd; alle oudere kinderen met het 
Goldberg-Shprintzen syndroom ontwikkelden een progressieve scoliose en infecties van de cornea. 
Follow-up van de 2 kinderen die gepubliceerd werden door Goldberg en Shprintzen bevestigde 
deze waarneming. Aangezien niet alle gevallen van de ziekte van Hirschsprung in combinatie met 
microcefalie en ontwikkelingsachterstand toegeschreven kunnen worden aan mutaties in KIAA1279 
of  ZFHX1B, is het zeer waarschijnlijk dat er andere genen bestaan waarin mutaties kunnen leiden 
tot deze specifieke combinatie van kenmerken.
Hoofdstuk 5 betrof klinische en moleculaire studies in een familie met een zus en broer met 
de combinatie van de ziekte van Hirschsprung en een syndroom; het Kaufman-McKusick syndroom 
dan wel het Bardet-Biedl syndroom.Beide syndromen zijn zeldzame autosomaal recessieve 
syndromen met een overlappend klinisch en moleculair spectrum. Sequentie analyse van 3 van de 
9 genen betrokken bij het Bardet-Biedl syndroom kon geen mutaties aantonen. Mutatie analyse 
van het RET gen toonde echter een verandering (Lys716Asn) aan bij het meisje, maar niet bij haar 
broer. Het is niet zeker dat deze variant een bijdrage levert aan het ontstaan van de ziekte van 
Hirschsprung in deze familie.
Deel 2 van dit proefschrift (Hoofdstuk 6) is gericht op de niet-syndromale vorm van 
de ziekte van Hirschsprung. Hoofdstuk 6 beschrijft een studie van een familie waar in meerdere 
generaties (in 2 takken) de ziekte van Hirschsprung voorkomt. Deze familie stelde ons in staat om 
een nieuw gen voor de ziekte van Hirschsprung te lokaliseren op de lange arm van chromosoom 4. 
Het bewijs hiervoor was niet significant, maar wel suggestief. Wij speculeerden dat de penetrantie 
in deze familie mogelijk RET-afhankelijk is. 
Hoofdstuk 7 (General discussion and future considerations) bevat een algemene discussie over 
de strategieën om genen betrokken bij de ziekte van Hirschsprung te identificeren en over onze 
bevindingen. Additionele genen betrokken bij de ziekte van Hirschsprung zullen zeer waarschijnlijk 
worden ontdekt in de toekomst, echter het vinden van deze genen zou wel eens moeilijk kunnen 
blijken te zijn, aangezien de individuele effecten klein zijn.
 De identificatie van deze genen is van groot belang voor de prognose en accurate 
erfelijkheidsadvisering. Aangezien het routinematig screenen van de huidige set van genen 
betrokken bij de ziekte van Hirschsprung niet mogelijk is, stellen wij richtlijnen voor die in de 
praktijk gebruikt kunnen worden door de kinderarts, kinderchirurg of klinisch geneticus wanneer 
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zij een kind met de ziekte van Hirschsprung treffen. Bovendien trachten wij een voorstel te doen 
voor een classificatiesysteem voor syndromen geassocieerd met de ziekte van Hirschsprung. Dit 
classificatiesysteem is gebaseerd op wat bekend is over de functie van de betrokken eiwitten in de 
ontwikkeling van het embryo.
Mits vruchtbare samenwerkingsverbanden tussen kinderchirurgische en klinisch genetische 
afdelingen zullen voortbestaan, zullen kinderen met de ziekte van Hirschsprung ongetwijfeld hiervan 
profiteren in de komende jaren. 
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Dankwoord
Het tot stand komen van een proefschrift heeft een geschiedenis. In dit dankwoord ligt deze historie 
besloten.
• Allereerst dank ik de drie families die de basis vormden voor de studies beschreven in dit 
proefschrift. U hebt vertrouwen in ons onderzoek gesteld en daarvoor ben ik u zeer 
dankbaar.
• Aan de basis van dit proefschrift stond een triumviraat. Prof.dr.H. Galjaard, Prof.dr.J.C. Molenaar 
en Dr.C. Meijers. Professor Galjaard en Professor Molenaar wil ik bedanken voor de 
mogelijkheid om de arts te zijn “met belangstelling voor de diagnostiek en behandeling van 
aangeboren anatomische afwijkingen, gedetacheerd op de kinderchirurgische afdeling van het 
Sophia Kinderziekenhuis” (NRC 11/11/1995). Uw belangstelling en steun door de jaren heen zijn 
voor mij zeer waardevol. Dr.C. Meijers. Beste Carel, ere wie ere toekomt. Jij bent het geweest 
die mij gedegen begeleidde bij mijn eerste wetenschappelijke stappen; je introduceerde mij 
bij Robert en de internationale HSCR Club, je leerde me hoe ik een verhaal kon schrijven/
vertellen (ultimate selling point) en je stimuleerde me om veel te lezen. Mijn dank is groot en 
oprecht.
• Mijn drie promotores. Prof.dr.B.A. Oostra. Beste Ben, je draagt uit dat je het belangrijk vindt 
dat artsen ook labwerk doen. Dank je wel voor de mogelijkheid om 2 jaar op jouw lab te 
werken. Jouw les dat je short cuts kunt nemen, maar tegelijkertijd volgens een stappenplan 
moet werken, is belangrijk om te onthouden. Prof.dr.D.Tibboel. Beste Dick, je bent de 
motor achter alle projecten tussen de afdeling Kinderchirurgie en Klinische Genetica. Dank 
hiervoor. Aan de 5 kinderchirurgische indexdiagnoses is nog veel genetisch te beleven; onze 
samenwerking krijgt een vervolg. Prof.dr.R.M.W. Hofstra. Beste Robert, jouw geloof in mijn 
kunnen en je continue begeleiding hebben er voor gezorgd dat deze geschiedenis een goede 
afloop kent. Dank je wel. Onze zoektocht naar HSCR genen gaat door. Wat ben ik vereerd en 
wat vind ik het bijzonder dat jij mijn promotor bent.
• De overige leden van de kleine commissie Prof.dr.S. Lyonnet, Prof.dr.H.G. Brunner en 
Prof.dr.W.F.M. Arts, dank ik voor uw bereidheid in de kleine commissie plaats te nemen. Dear 
Stan, thank you for your willingness to take part in my thesis defense.
• Prof.dr.M.H. Breuning en Prof.dr.D. Lindhout. Jullie begeleiding vanuit de klinische genetica in 
het begin van het onderzoek heb ik als prettig en leerzaam ervaren. 
• Prof.dr.J.W. Wladimiroff. Als afdelingshoofd biedt u mij de mogelijkheid om mij straks als staflid 
verder te bekwamen op het gebied van aangeboren anatomische afwijkingen. Dank u wel voor 
die kans.
• Mijn drie opleiders in de Klinische Genetica wil ik danken voor hun rol als leermeester. 
Prof.dr.M.F. Niermeijer. Beste Professor Niermeijer, in het eerste jaar coachte u mij intensief 
in alle facetten van het vak. U leerde mij te benoemen wat moeilijk kan zijn in de counseling, 
de genetische hulpvraag te exploreren, en de differentiaal diagnostische overwegingen uit te 
werken. Dr.E.J. Meijers-Heijboer. Beste Hanne, dank je wel voor de mogelijkheid om 2 jaar 
full time in het lab te werken en mij vrij te spelen van patiëntenzorg zodat het vinden van het 
gen mogelijk werd. Onder jouw opleiderschap leer ik hart voor de patiënt en passie voor de 
wetenschap te combineren. A.J.M. Hoogeboom. Beste Jeannette, jouw kennis van en ervaring 
in de syndromologie zijn ongeëvenaard. Dank je wel dat je dat deelt en overbrengt. Mijn 
dysmorfologische pluis-niet pluis gevoel is dankzij jou goed ontwikkeld.
• Vier personen hebben mijn keuzes voor en binnen de Klinische Genetica op afstand 
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beïnvloed. Prof.dr.H.M. Evenhuis. Beste Heleen, je liet me inzien dat ik onderzoeks-minded 
was. Prof.dr.R.C.M. Hennekam. Beste Raoul, door jouw praatje voor de co-assistenten 
Kindergeneeskunde in het AMC wist ik het zeker; ik was gegrepen door de syndromologie. 
Dr.P.J. Willems. Beste Patrick, dank voor je voortdurende support. Niemand schrijft zo mooi 
als jij. Prof.dr.J.P. Fryns. Professor Fryns, mijn stage in Leuven van 3 maanden was intensief 
en leerzaam, dank u en ook dank aan uw team (in het bijzonder Prof.dr.K. Devriendt en 
Prof.dr.E. Legius).
• De drie analisten die mij de basics bijbrachten van DNA onderzoek. Robert van der Helm. 
Robert, dank voor je uitleg “hoe doe ik mijn eerste PCR”en vriendschap. Jan Osinga. Jan, dat ik 
welkom was voor een etentje bij jullie thuis en dat ik bij je op je werkkamer mocht zitten, heb 
ik erg gewaardeerd. Dank je wel voor het screenen van de additionele GOSHS families en al 
het andere HSCR werk. Guido Breedveld (the labmaster). Guido, dank voor je heldere uitleg 
en geduld om samen vele sequenties te bekijken.
• Drie vrouwen leverden een belangrijke bijdrage aan mijn wetenschappelijke vorming. 
Dr. A. Bertoli-Avella. Dear Aida, dank voor je toewijding aan de HSCR projecten. “Wie goed 
doet, goed ontmoet” is op jou van toepassing. Dr. E. de Graaff. Beste Esther, je enthousiasme 
voor het ontrafelen van de genetica van aangeboren afwijkingen werkt aanstekelijk. KIAA1279 
stelt ons nog een groot aantal vragen, hopelijk kunnen we de komende jaren er samen nog 
een paar beantwoorden. Dr. G.M.S (“ik ben geen telefoon”) Mancini, mijn supervisor van het 
grootste deel van mijn klinische werk en mentor. Cara Grazia, je combineert complex klinisch 
genetisch werk met wetenschappelijk onderzoek. Een voorbeeld om na te volgen. Dank voor 
je steun.
• Ik wil alle collega’s van de kinderchirurgie bedanken voor de prettige samenwerking. In het 
bijzonder dank ik Dr. R.A. Langemeijer, de HSCR kinderchirurg.
• Collega’s van de WZD. Dank voor jullie interesse voor mijn werk in het lab. Staf van de sectie 
counseling. Jullie unanieme steun voor mijn aanstelling als staflid per 1-1-2006 waardeer ik 
zeer, ik weet dat een aantal van jullie zich daar extra voor heeft ingespannen! Dank jullie 
wel. De AIOS/AGNIO groep is een (h)echte en unieke groep. Dank je wel Rogier, Marleen, 
Liselotte, Marieke J, Marieke, Ingrid, Ingrid K, Muriel, Esther en Yvonne voor jullie collegialiteit, 
luisterende oren en helpende handen.
• Tom de Vries Lentsch. Beste Tom, je succes met de opmaak van vele boekjes maakt dat je 
het razend druk hebt, dank voor je mooie werk.   Ko Hagoort. Beste Ko, dank je wel voor 
je taaltechnische correcties. Dr. C.P. Torfs. Dear Claudine, thank you very much for your 
comments.
• Collega’s van het researchlab van de afdeling Klinische Genetica Rotterdam. Jullie maken de 
sfeer en zorgen ervoor dat passanten, zoals ik, zich meer dan welkom voelen. Dank voor 
de labtechnische hulp en adviezen. Dr. A.J. Verkerk. Beste Annemieke, we hebben allebei 
inmiddels een andere werkplek, maar ons contact is wat mij betreft blijvend (dank voor je 
mooie kaartjes!) 
• Collega’s van het researchlab van de Medische Genetica in Groningen. Het gevleugelde 
“Tast toe” (deze alliteratie uitgesproken met twee harde T’s) bij de verjaardagskoffie. Dat is 
Groningen. Bedankt Groningse HSCR groep (Greg Burzynski, Joke Verheij, Ivan Plaza Menacho 
en Jan Osinga) voor heuse HSCR werkbesprekingen.
• Collega’s van de 24e. Sectiehoofden en analisten. De overdracht van jullie kennis en kunde 
maakt onze opleiding tot klinisch geneticus compleet. In het bijzonder wil ik Dr. D.J.Halley, 
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sectiehoofd DNA-diagnostiek, bedanken. Beste Dicky, dank je wel dat je mijn wens om voor 
langere tijd in het lab te willen werken, steunde en stimuleerde. Dr. P.J. Poddighe, beste Pino 
dank je wel voor de ZFHX1B FISH in de Rotterdamse GOSHS familie.
• Alle mede-auteurs wil ik bedanken voor hun bijdrage. 
• Dear Bob Shprintzen, Jeanne Amiel, Jane Hurst, Carole McKeown, Helen Murphy, Kristi Jones, 
Meredith Wilson, Anita Rauch, Christiane Zweier, Michel Goossens, thank you very much for 
sharing with us your clinical data on (possible) GOSHS families. Prof.dr.P.J. van der Spek, Rachel 
Schot en Justine Peeters wil ik bedanken voor de expressie array data. De kinderpathologen Dr. 
R.R. de Krijger en Dr. J.den Hollander dank ik voor de prettige samenwerking. Dr. M.H. Lequin, 
beste Maarten, dank je wel voor je revisie van de MRIs van de GOSHS families.
• Mijn collega-vriendinnen, mijn eigen 3-M syndroom (kenmerken: katholieke opvoeding, 
gevoelig en open, moeder) (en dit is dus niet CUL). Mijn maatjes. Marja Wessels. Lieve Marja, 
ik voelde je vriendschap vanaf onze eerste ontmoeting. Ik bewonder je kracht, je levensfilosofie 
en je vermogen om niet te veroordelen. Dr. Marieke van Dooren. Lieve Marieke, jij bent mijn 
paranimf en ik was die van jou. Je “hoe is het El”, wijze raad, oneindige energie, en warme 
vriendschap. Het is me dierbaar. Mieke van Haelst. Lieve Mieke, onze telefoon gesprekken zijn 
in de plaats gekomen van de lunches bij de Graaf. Dank voor je stimulans en meedenken bij 
ingewikkelde keuzes. En bij elk syndroom hoort nog een uitzonderlijk kenmerk: Liselotte van 
Hest. Lieve LVH, je bent mijn carpool maatje en dan spreken we over het werk en het leven. 
Waren wij maar af en toe zo stoer als Sara K!
• Mijn schoonouders. Lieve Hans en Leny. Jullie liefde en zorg voor jullie (schoon)kinderen zijn 
groot. Ja, we genieten en hebben en houden het goed. Lieve Stef (wat zou mijn leven anders 
zijn als wij elkaar niet zouden hebben ontmoet bij de Mignon), Cat, Gil en Eer, ik bof met 
jullie!
• Mijn oom Joop en tante Marion, de schakels naar mamma. Lieve Joop en Marion, jullie liefde 
en aandacht hebben ons altijd omringd. Andrea. Lieve Andrea, je deed Yvonne een belofte. Als 
jonge vrouw bevat ik nu de omvang van die belofte. Dank voor je liefde en zorg. Mijn nichtjes 
Anouk, Nenneke, Gonneke en Marieke. Onze familiegeschiedenis maakte dat we als kind veel 
met elkaar optrokken. Ik zie in jullie warme, zorgzame vrouwen. Lieve Jacqueline dank je wel 
voor je belangstelling voor mijn onderzoeksperikelen.
• Lieve Marjan, broer Sander, zus Rianne; het gezin dat jullie met pappa vormen is warm en 
hecht.
• Mijn ouders. Jullie vormden onze basis. Leerden ons leren, het Leven en lief te hebben. 
Lieve pappa, gelijkenissen tussen jou en je oudste dochters zijn er voldoende. Zie jij ze ook? 
Ik bewonder je vermogen om een nieuwe start te maken in het leven. Lieve mamma, in 
herinnering al 25 jaar. Kijk, mamma’s grote meisjes zijn groot.
• Lieve Eva. Eva leest letters. Alice maakt letters. Wat zegt Alice? Eva is lief! Kus van je tante. 
Mijn zwager Bert. Lieve Bert, je vroeg me geregeld of het proefschrift vorderde. Van ons 
dokters 4-tal heb je ook deze stress ervaren. Dank voor je tips.
• Mijn tweelingzus Helen. Lieve Helen, lieve bol. Je bent als baby 1 mijn grote zus. Jouw liefde is 
echt onvoorwaardelijk, zorgt ons ene ei daarvoor? Ons leven heeft zich heel lang in volmaakte 
symbiose voltrokken, samen naar school, samen geneeskunde studeren, samen op kamers 
wonen. Uiteindelijk kozen we gelukkig een andere man en een andere specialisatie, hoewel ik 
ook in die keuzes meer overeenkomsten zie dan verschillen.
• Jurgen. Lieve Jur, lieve man. Dank je voor jou. Wat hebben we het toch goed samen.
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